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Nasopharyngeal carcinoma (NPC) is a cancer originating in the nasopharynx. 
It is vastly more common in Southern China, Southeast Asia, Japan, and the 
Middle East/North Africa than elsewhere, with viral, dietary and genetic 
factors implicated in its causation. The treatment for NPC includes 
radiotherapy and chemotherapy. However, one of the major drawbacks of the 
treatment is the non-tumour specific killing. Thus alternative therapeutic that 
could target cancer cells would be desirable. The TNF receptor family 
member, TNF-family related apoptosis inducing ligand (TRAIL) has shown 
promise as a target-specific agent against tumour cells. The heightened interest 
in evaluating the potential use of TRAIL in the clinical settings stems from 
observations that TRAIL receptors, DR4 and DR5, are selectively expressed 
on tumour cells. To that end, TRAIL is under investigation for their potential 
to be a NPC therapeutic. We recently demonstrated that TRAIL is able to 
induce apoptosis in two NPC cell lines, HK-1 and C666-1. It is evidenced by 
DNA fragmentation, caspases-8, -9 and -3 activation, and significant 
inhibition of tumour colony forming ability of the cells upon TRAIL exposure. 
Serendipitously, we found that there is a non-classical early activation of 
effector caspase-3 in the NPC model. We link this to the presence of caspases-
3 in the cell surface membrane lipid raft in association with a novel membrane 
protein, transmembrane and tetratricopeptide repeat containing 2 (TMTC2). 
The presence of caspases-3 at the lipid raft allows the close proximity of 
caspsase-3 to the death-inducing signaling complex (DISC) in the lipid rafts 
even before death trigger.  As a result, upon trigger, caspases-3 can be 
ix 
 
activated at a much earlier time point. Intrigued by the findings, we moved on 
to investigate the effect of TRAIL on TMTC2. Exposure of HK-1 cells to 
TRAIL induces an increase in the level of TMTC2. The induction of TMTC2 
by TRAIL was dependent on the TRAIL-induced caspase activation and 
peroxynitrite accumulation, with the caspases acting upstream of peroxynitrite. 
In addition, preliminary work in this thesis seems to suggest that the level of 
TMTC2 within the cells reflects the cell’s sensitivity towards TRAIL. 
Knocking down of TMTC2 in HK-1 cells and overexpression of TMTC2 in 
C666-1 cells is able to reduce and enhance the TRAIL sensitivity of the cells 
respectively.  
 
Collectively, the work in this thesis highlights the potential of TRAIL as a 
NPC therapeutic, along with implications for TMTC2 as a biomarker of cell’s 
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1.1 Prevalence of cancer  
Cancer is the rapid creation of abnormal cells that grow beyond their usual 
boundaries and which can then invade adjoining parts of the body and spread 
to other organs. According to the World Cancer Report released by the World 
Health Organisation (WHO), in the year 2000, malignant tumours were 
responsible for 12 per cent of the nearly 56 million deaths worldwide. In many 
countries, more than a quarter of deaths are attributable to cancer. In 2000, 5.3 
million men and 4.7 million women developed a malignant tumour and 
altogether 6.2 million died from the disease. The report also reveals that 
cancer has emerged as a major public health problem in developing countries, 
matching its effect in industrialised nations. Deaths from cancer worldwide are 
projected to continue rising, with an estimated further increase by 50% to 15 
million new cases in the year 2020. 
 
1.2 Development of oncogenicity 
Homeostasis is the property of a system of an organism or cell to maintain 
internal equilibrium by adjusting its physiological processes. It plays an 
important role in ensuring a functional and healthy body. Cancers arise when 
this equilibrium goes astray. It occurs when proto-oncogenes switch into their 
oncogenic forms, leading to the process of tumourigenesis where cells develop 
capabilities for sustained proliferation or to resist death signals. This can be 
attributed to a variety of factors, among which is the overexpression or 
constitutive activation of pro-survival proteins such as B-cell lymphoma 2 
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(Bcl-2) or Akt/Protein kinase B (PKB). Impediment of cell death signalling 
within a cell, like increased levels of inhibitors of apoptosis (IAP) or reduction 
in pro-death proteins such as the death receptors or caspases, endows the cell 
with a survival advantage, rendering it insensitive to homeostatic commands 
to commit suicide. These observations provide novel effector pathways 
regarding growth and cell fate regulation, presenting novel avenues for 
intervention towards oncogenesis. 
 
2. Nasopharyngeal carcinoma 
Nasopharyngeal carcinoma (NPC) is a non-lymphomatous, squamous cell 
carcinoma occurring at the nasopharynx, which is located behind the nose and 
above the back of the throat. The clinical presentation includes the presence of 
asymptomatic cervical neck mass typically localised to the posterior cervical 
triangle or the superior jugular nodal chain. Other clinical signs and symptoms 
comprise of nasal obstruction, nasal discharge, epistaxis, pain, serious otitis 
media, otalgia, hearing loss and headache. The signs and symptoms are often 
subtle and nonspecific, thus causing a delay in diagnosis. 
 
2.1 Classification 
In 1978, the histological classification guideline proposed by the WHO 
categorised NPC into three groups: Type I (keratinising squamous cell 
carcinoma), Type II (non-keratinising carcinoma) and Type III 
(undifferentiated carcinoma). Then in 1991, WHO introduced a new 
classification scheme for NPC. NPC are now divided into 2 histological 
variant; keratinising squamous cell carcinoma (Type I of the former 
classification) and non-keratinising carcinoma (Types II and III of the former 
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classification combined into a single category). The non-keratinising type is 
further subdivided into non-keratinising differentiated and non-keratinising 
undifferentiated (1).  
 
2.2 Epidemiology  
NPC is a relatively rare malignancy in most parts of the world. It accounts for 
2% of all head and neck squamous cell carcinomas, with an incidence of 0.5 to 
2 per 100,000 in the United States (2). However, it is endemic in many 
geographical regions, including Southern China, Southeast Asia, Japan, and 
the Middle East/North Africa (2, 3). Ho (4) reported that NPC is the third most 
common malignancy among men, with an incidence of between 50 per 
100,000 in the Guangdong Province of Southern China. Emigration from high- 
to low-incidence areas such as the United States and Canada reduces the 
incidence of NPC in first-generation Chinese, but it still remains at seven-
times the rate in Caucasians (5).  
 
2.3 Etiology 
The etiology of NPC seems to follow a multi-step process, in which chronic 
infection with oncogenic gamma herpes virus Epstein-Barr virus (EBV), 
environmental and genetic factors all seem to play an important role (2).  
 
EBV exists worldwide, infecting over 95% of the global adult population (6). 
Although primary EBV infection is typically subclinical, the virus is 
associated with the later development of several malignancies, including NPC 
(3). Elevated titer of EBV-associated antigens has been identified in neoplastic 
cells of virtually all cases of NPC. The clonal EBV genome is also 
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consistently detected in invasive carcinomas and high-grade dysplastic lesions 
(2). All these suggest a critical role of EBV in the pathogenesis of NPC in 
endemic areas.  
 
Non-viral exposure associated with the risk of NPC involves the consumption 
of salt-preserved food, a dietary staple in several NPC endemic areas (3, 7). 
Thus, this dietary staple pattern may explain part of the international 
distribution of NPC incidence. The carcinogenic potential of salt-preserved 
fish is supported by experiments in rats, which develop malignant nasal and 
nasopharyngeal tumours after salted fish consumption (8-10). The process of 
salt preservation is inefficient, allowing fish and other foods to become 
partially putrefied. As a result, these foods accumulate significant levels of 
nitrosamines, which are known carcinogens in animals (11, 12). Salt-preserved 
fish also contain bacterial mutagens, direct genotoxins, and EBV-reacting 
substances (13-15), any or all of which could also contribute to the observed 
association.  
 
Several associations have been described between the frequency of human 
leukocyte antigen (HLA) class I genes in certain populations and the risk of 
developing NPC. For example, increased risk of NPC was observed in 
individuals with the HLA-A2 allele, particularly HLA-A0207 (16). Recent 
genome wide association studies confirmed involvement of HLA molecules in 








Radiation therapy is often the initial treatment option for NPC (19). With the 
innovation of treatment techniques like the three-dimensional conformal 
radiotherapy, intensity-modulated radiotherapy and image-guided 
radiotherapy, satisfactory results have been achieved in early stage of the 
disease (20). However, the majority of NPC present at locally advanced stage 
and results are disappointing when radiation therapy alone is being used (20-
22). Thus for the more advanced stage of NPC, concurrent Cisplatin or 5-
Fluorouracil and radiotherapy are often used to improve survival (23-25). 
Generally there are 3 ways in which this combination treatment can be 
administered. Firstly, chemotherapy can be done at the same time as radiation 
therapy (26). When the two treatments are combined, chemotherapy enhances 
the effectiveness of radiation therapy. This combined treatment is called 
concomitant therapy. However, side effects of chemotherapy are added to the 
side effects of radiation therapy, making concomitant therapy more 
intolerable. Secondly, chemotherapy can be done after radiation therapy. This 
is called adjuvant chemotherapy (27). Adjuvant chemotherapy is used to 
attack any remaining cancer cells in your body, including those that may have 
broken off from the original tumour and spread elsewhere. Lastly, 
chemotherapy is done before radiation therapy and this is known as 
neoadjuvant chemotherapy (28). More research is needed to determine 
whether neoadjuvant chemotherapy can improve survival rates in people with 
nasopharyngeal carcinoma. 
 
Surgery is not often used as a treatment for NPC. It is only used when the 
NPC does not respond to any other treatment.  
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3. Cell death 
Cell death is a normal physiological process. Almost every aspect of life is 
intimately dependent on the appropriate regulation of cell death. When the 
tight regulation of cell death breaks loose, it either contributes to or forms the 
basis of most human diseases pathogenesis. Cell death can be classified 
according to its morphological appearance (which may be apoptotic, necrotic, 
autophagic or associated with mitosis), enzymological criteria (with and 
without the involvement of nucleases or of distinct classes of proteases, such 
as caspases, calpains, cathepsins and transglutaminases), functional aspects 
(programmed or accidental, physiological or pathological) or immunological 
characteristics (immunogenic or non-immunogenic) (29-31). 
 
3.1 Necrosis 
Until 1972, the term “necrosis” was used for all types of cell death. Necrosis 
occurs after an extensive tissue injury such as ischemia and is characterised by 
cytoplasmic swelling and swelling of organelles leading to plasma membrane 
rupture and subsequent loss of intracellular contents into the extracellular 
milieu. This results in inflammation and recruitment of immune cells to 
eliminate cellular debris and initiate the tissue repair process (32). Necrosis is 
a passive process that does not require adenosine triphosphate (ATP). ATP 
concentration is an important parameter in the decision for the cell to either 
undergo necrosis (low concentration of ATP) or apoptosis (high concentration 




Necrosis was initially classified as a disordered and accidental form of cell 
death until recent studies suggested that this may not be true. Rather, it 
appears that necrotic cell death can be a regulated event that contributes to the 
development and maintenance of organismal homeostasis. This is supported 
by the fact that necrosis can occur during development (for example the death 
of chrondrocytes controlling the longitudinal growth of bones) (34) and in 
adult tissue homeostasis (for example in intestinal epithelial cells) (35). In 
addition, necrosis can be triggered by specific plasma membrane receptors by 
their physiological ligands (32). This observation implies that specific signal 
transduction pathways are connected to the induction of necrosis. Several 
mediators have been implicated in necrotic cell death, but it is still unclear 
how they interrelate with each other. Typical alterations that accompany 
necrosis include mitochondrial alterations, such as uncoupling and production 
of reactive oxygen species, or mitochondrial membrane permeabilisation (36). 
Additionally, lysosomal membrane permeabilisation, nuclear changes and 
increases in cytosolic concentration of calcium resulting in mitochondrial 
overload and activation of non-caspase proteases, like calpains and cathepsins, 
have also been reported to induce necrotic cell death (37, 38). A crucial role 
for the serine/threonine kinase, receptor-interacting protein 1 (RIP1) has been 
demonstrated in several, but not all instances of necrotic death (39, 40). 
 
3.2 Autophagy 
Autophagy is a process of self-cannibalisation. Cells capture their own 
cytoplasm and organelles and consume them in lysosomes. The resulting 
breakdown products are inputs to cellular metabolism, through which they are 
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used to generate energy and to build new proteins and membranes. Autophagy 
preserves the health of cells and tissues by replacing outdated and damaged 
cellular components with fresh ones. In starvation, it provides an internal 
source of nutrients for energy generation and thus, survival. Autophagy is an 
essential part of growth regulation and maintenance of homeostasis in 
multicellular organisms (41). It is morphologically defined as a type of cell 
death that occurs in the absence of chromatin condensation, accompanied by 
massive autophagic vacuolisation (double-membraned autophagic vacuoles) of 
the cytoplasm. In autophagy, a double- or multi-membrane–bound structure, 
called the autophagosome or autophagic vacuole, is formed de novo to 
sequester cytoplasm. Then, the vacuole membrane fuses with the lysosome to 
deliver the contents into the organelle lumen, where they are degraded and the 
resulting macromolecules recycled (42). 
 
Many genes involved in autophagy have been discovered and they are now 
called autophagy-related genes (Atg). Many of them are involved in the 
process of autophagosome formation that features two ubiquitin-like 
conjugation systems well-conserved among eukaryotes: the Atg12–Atg5 and 
the Atg8(LC3)-phosphatidylethanolamine (PE) systems (43). Light chain 3 
(LC3) is the only reliable marker of autophagosome formation in mammalian 
cells, with the relative amount of LC3-II reflecting the abundance of the 
autophagosomes. Autophagic cells are characterised biochemically by 







In the mid-nineteenth century, many observations have indicated that cell 
death plays a considerable role during physiological processes of multicellular 
organisms, particularly during embryogenesis and metamorphosis (46). The 
term programmed cell death was introduced in 1964, proposing that cell death 
during development is not of accidential nature but follows a sequence of 
controlled steps leading to locally and temporally defined self-destruction 
(47). Eventually, the term apoptosis had been coined in order to describe the 
morphological processes leading to controlled cellular self-destruction and 
was first introduced in a publication by Kerr et. al. (48).  
 
Apoptosis is an active programmed cell death that involves the activation of 
tightly regulated intracellular machinery that has been conserved throughout 
evolution. It plays an important role in the development of multicellular 
organisms and in the regulation and maintenance of the cell populations in 
tissues upon physiological and pathological conditions (49). Therefore, 
deregulation of apoptosis has been linked to various disease pathologies, 
including neurodegenerative diseases, autoimmunity and cancer.  
 
Apoptotic cells are characterised by distinct morphological changes, such as 
cellular shrinkage, membrane blebbing, nuclear chromatin condensation and 
DNA fragmentation (50-52). During the early stage of apoptosis, cell 
membrane integrity is maintained while subtle changes like externalization of 
phosphatidylserine occur (53).  Eventually, the entire cell breaks into 
membrane-bound fragments, termed apoptotic bodies (54), which are engulfed 
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by surrounding phagocytes (macrophages and dendritic cells) without eliciting 
an inflammatory response.  
 
4. Molecular mechanisms of apoptosis  
Apoptosis is a tightly regulated and at the same time highly efficient cell death 
program which requires the interplay of a multitude of factors. It can occur via 
two main signaling pathways, the intrinsic pathway and the extrinsic pathway 
(Fig 1).   
 
The intrinsic pathway is triggered from within the cell by developmental cues 
or severe cellular stress, such as DNA damage. The extrinsic pathway is 
activated when a pro-apoptotic ligand, such as endogenous Fas-ligand (FasL) 
or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), 
binds to its pro-apoptotic death receptors, such as Fas, or death receptor 4 
(DR4) and death receptor 5 (DR5). Destruction of the cell is ultimately carried 
out by intracellular protease enzymes called caspases. The caspases upon 
activation by the intrinsic and/or extrinsic pathways will destroy cellular 
proteins that are vital for cell survival. 
 
In this section, a general overview of the basic apoptotic signalling pathways 
and the sophisticated interplay between factors responsible for the promotion 








Figure 1: Two major apoptotic death signalling pathways in the cell 
The extrinsic death pathway is exemplified by binding of TRAIL to TRAIL death receptor, 
while the intrinsic or mitochondrial apoptotic signalling is usually a result of cellular insults 
such as DNA damage. The two pathways are interlinked by Bid, which could be cleaved by 
caspase-8 and subsequently promote mitochondrial cytochrome c release.  












4.1 Caspase family 
At the heart of the apoptotic machinery lies a family of proteases known as 
caspases. The name “caspase” denotes their function: Cysteine-dependent 
ASPartyl-specific proteASE. Their catalytical activity depends on a critical 
cysteine-residue within a highly conserved active site penta-peptide QACRG 
(56). Caspases are highly homologous to C. elegans cell death gene CED-3. 
The mammalian family contains many members (Fig 2), a distinct class of 
caspases (caspase-1, -4, -5 and -12) are involved in cytokine processing and 
inflammation whilst the remaining family members are involve in apoptosis 
(57-59). Caspases share some common properties like having a conservative 
penta-peptide active site containing a cysteine residue; they are all cysteine 
proteases that recognise a tetra-peptide site containing an aspartate residue; 
and they are regulated at a post-translational level, ensuring their rapid 
activation upon induction (60, 61).  
 
Caspases are synthesised as inactive zymogens made up of three domains: a 
pro-domain at the NH2-terminal, a 17-21kda large subunit and a 10-12kda 
small subunit (62). Under the pro-apoptotic stimuli, procaspases become 
proteolytically cleaved between these domains. This is followed by association 
of the large and small subunits to form a heterodimer. Subsequently, two 
heterodimers come together to form a tetramer, the functional unit of caspases 
(63). Activated caspases are highly selective in their substrate, exhibiting an 
absolute requirement for cleavage after an aspartate residue. Substrate 
specificity is further defined by at least three other amino acid residues at the 
NH2-terminal of the aspartate residue (64). 
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There are two types of caspases: initiator caspases (caspase-8 and caspase-9) 
and effector caspases (caspase-3, caspase-6 and caspase-7). Whereas the 
executioner caspases possess only short pro-domains, initiator caspases 
possess long pro-domains, containing death effector domains (DED) in the 
case of procaspases-8 or caspase recruitment domains (CARD) as in the case 
of procaspase-9. In response to apoptotic stimuli, either ligand binding to cell 
surface death receptors (extrinsic apoptosis pathways) or in response to signals 
originating from inside the cell (intrinsic apoptosis pathways), the initiator 
caspases are recruited to death signalling protein complexes with help of 
adaptor proteins via their pro-domains. At the death signalling protein 
complexes, the initiator caspases are brought into close proximity and are 
activated through autoproteolytic cleavage (56, 65). The activated initiator 
caspases then amplify the death signal by cleaving inactive pro-forms of 
effector caspases such as caspase-3, capase-6 and caspase-7, thereby 
activating them (62). Their activation results in the cleavage of numerous key 
cellular substrates such as poly(ADP-ribose) polymerase (PARP) or inhibitor 
of caspase-activated DNAse (ICAD) (66, 67). PARP is a nuclear protein 
implicated in DNA repair and is one of the earliest proteins cleaved by 
caspases (68). Caspase cleavage and inactivation of ICAD permits the release 
and translocation of caspase-activated DNAse (CAD) to the nucleus where it 
is responsible for internucleosomal DNA cleavage, generating 
oligonucleosomal DNA fragments (69, 70). Caspases also mediate nuclear 
shrinkage by cleaving lamins (71) and membrane blebbing by targeting 
proteins such as Rho-associated kinase 1 (ROCK1), p21 activated kinase 




















Figure 2: Structure of the caspase family members and their associated function 
The caspase family can be subdivided into initiators, which are able to auto-activate and 
initiate the proteolytic processing of other caspases, and effectors, which are activated by 
other caspase molecules. The effector caspases cleave the vast majority of substrates during 
apoptosis.  
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4.2 Inhibitor of apoptosis 
The IAP gene was first identified in baculovirus where it was shown to 
enhance virus replication by protecting infected cells from death. Since then, 
IAP homologues have been identified in a wide range of organisms (75). The 
IAP proteins are thought to provide the final level of regulation of apoptosis 
by inhibiting caspase-3, -7 and -9 (76-78). They are characterised by one or 
more tandem repeats of an evolutionarily conserved 70 amino acids domain 
termed baculovirus IAP repeat (BIR) at their NH2-terminal (79-81) that 
enables them to directly bind to and inhibit caspases. Some IAP contains a 
COOH-terminal RING finger domain that has been identified as an essential 
motif for the activity of ubiquitin ligase E3 which brings about the 
ubiquitinylation and degradation of pro-apoptotic proteins (82-85). To date, 
there are eight IAP members in humans: neuronal apoptosis-inhibitory protein 
(NIAP), cellular inhibitor of apoptosis protein 1 (cIAP1), cellular inhibitor of 
apoptosis protein 2 (cIAP2), X-linked IAP (XIAP), survivin, BRUCE, 
melanoma IAP (ML-IAP)/Livin and IAP-like protein-2 (ILP2) (75) (Fig 3). 
The IAP proteins can be divided into three classes based on the presence or 
absence of a RING finger and the homology of their BIR domains (86). 
 
Class 1 IAP contain homologous BIR domains and a RING finger motif.  
Members of this class include XIAP, cIAP1, cIAP2, Livin and ILP-2. XIAP, 
the best characterised IAP so far, is generally recognised as the most potent 
endogenous caspase inhibitor. XIAP has three BIR domains, BIR1, BIR2, and 
BIR3, which have high affinity but unequal functions to caspases. The BIR2 
domain and the linker region between BIR1 and BIR2 specifically bind and 
inhibit caspase-3 and caspase-7. The BIR2 domain lies across the active site of 
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caspase-3 and inhibits the activity of caspase-3 by blocking its substrate-
binding pocket. The caspase-9 inhibitory activity of IAP requires both the 
BIR3 and RING domain. Without physically binding to the active site of 
caspase-9, the BIR3 domain forms as a heterodimer with monomeric caspase-
9, thereby preventing the dimerisation and activation of caspase-9 (87-89). 
cIAP1 and cIAP2 are structurally related to XIAP with three BIR domains and 
a RING finger. They bind and inhibit caspase-3 and -7, albeit less strongly 
than XIAP (90). Livin and ILP-2 have a RING finger and only one BIR 
domain, but their BIR domain is most homologous to the BIR3 domain of 
XIAP, cIAP1, and cIAP2 (hence their inclusion in this class). Livin inhibits 
caspases-3 and -9 but does not bind or inhibit caspases-1, -2, -6 or -8 (91) and 
ILP-2 inhibits caspase-9, but not caspases-3, -7 or -8 (92).  
 
The class 2 IAP family member NAIP has three BIR domains but no RING 
finger motif. Its BIR domains are more distantly related to the BIR domains of 
the class 1 IAP. It inhibits caspases-3 and -7, but not caspases-1, -4, -5 or -8 
(93). 
 
For class 3 IAP member, surviving, it contains only a single BIR domain and 
no RING finger. Survivin can bind to second mitochondria-derived activator 
of caspase/direct inhibitor of apoptosis-binding protein with low pI 
(Smac/DIABLO), a known inhibitor of XIAP and prevent its interaction with 
XIAP. Survivin can also block apoptosis independently of caspase inhibition 





So far, what is being described is IAP inhibiting caspases. However, active 
caspases can also cleave and inactivate IAP.  XIAP, cIAP1 and ML-IAP/Livin 
have been reported to undergo specific and functional cleavage by caspases 
(95-98). Cleavage of XIAP produces two subunits: one that comprises of BIR1 
and BIR2, and the second, BIR3-RING. The NH2-terminal BIR1-2 fragment 
has a reduced propensity to inhibit caspase-3 and -7, while the BIR3-RING 
still retains its ability to inhibit caspase-9.   
 
In some cases, IAP-mediated inhibition of caspases can be prevented by an 
IAP antagonist such as Smac/DIABLO (99), Omi/Htra2 and XIAP associated 
factor 1 (XAF-1) that binds to the BIR domains of IAP (100, 101). 
Mitochondrial Smac/DIABLO (102), along with cytochrome c, is released into 
the cytosol and binds to IAP during apoptosis, eliminating the interaction 
between caspases and IAP, thus antagonising their inhibitory activity on 
caspases while XAF-1, a nuclear protein, has been observed to sequester 














Figure 3: IAP family members 
Proteins of the IAP family include BRUCE/Apollon, ILP2, ML-IAP/Livin,  survivin, NAIP, 
cIAP1, cIAP2 and  XIAP. The eight mammalian IAPs are characterized by different 
composition of functional domains: BIR, RING and CARD.  
















4.3 Bcl-2 family 
Apoptosis is also controlled by a highly conserved family of proteins: Bcl-2 
proteins. The gene coding for Bcl-2 was the first to be identified as a proto-
oncogene in B lymphocytes (105). Mammalian Bcl-2 has at least 20 relatives, 
all of which contain at least one conserved Bcl-2 homology (BH) domain 
(BH1 to 4). The Bcl-2 family is divided in two groups: the anti-apoptotic and 
the pro-apoptotic members (106) (Fig 4). 
 
The anti-apoptotic members includes Bcl-2, B-cell lymphoma-extra-large 
(Bcl-XL), Bcl-W and myeloid cell leukemia sequence 1 (Mcl-1). They contain 
all 4 BH domains (with the exception of Mcl-1, lacking a BH4 domain) as 
well as a hydrophobic COOH-terminal transmembrane domain targeting them 
to the nucleus envelope, the endoplasmic reticulum (ER) or the outer 
mitochondrial membrane (OMM). Bcl-2 is an integral outer mitochondria 
membrane protein under normal physiological conditions and serves to 
maintain mitochondria membrane integrity, preventing the release of 
apoptogenic proteins from the mitochondria. It has also been found to play a 
role in ER stress induced apoptosis, whereby it modulates ER calcium 
homeostasis through enhancing calcium transport across the ER membrane 
(107). Bcl-XL , Bcl-W and Mcl-1 have been less studied than Bcl-2 but were 
shown to be powerful anti-apoptotic proteins nonetheless (108-112). Mcl-1 
and Bcl-XL are two major anti-apoptotic Bcl-2 family proteins expressed in 
the liver and cooperatively control hepatic integrity during liver development. 
Mcl-1 has also been found to be involved in cortical neurogenesis and for 
ensuring the survival of neurons after DNA damage. Bcl-W mediates survival 
of post-mitotic Sertoli cells and it has been observed that mice containing 
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mutant Bcl-W display progressive and nearly complete testicular 
degeneration. 
 
The other Bcl-2 family members, the pro-apoptotic members can be further 
sub-divided into two groups: the Bcl-2-associated X (Bax) family proteins and 
the BH3-only proteins (113).  
 
The Bax family proteins include Bax, Bcl-2 homologous antagonist killer 
(Bak) and Bcl-2-related ovarian killer (Bok). They contain the domains BH1 
to BH3. Bax is found in the cytoplasm under physiological conditions. In the 
presence of an apoptotic stimulus, Bax translocates from the cytosol to the 
mitochondria, where it oligomerises and becomes inserted into the OMM to 
form a pore structure (36, 114). On the other hand, Bak is an oligomeric 
integral mitochondria membrane protein which changes its conformation to 
form larger aggregates that compromises mitochondrial membrane integrity 
during apoptosis. Oligomerisation of Bax/Bak is believed to contribute to the 
permeabilisation of the OMM, either by forming channels allowing 
cytochrome c release (115, 116) and/or by interacting with components of the 
mitochondrial permeability transition pore complex (PTPC), such as voltage-
dependent anion-selective channel protein 1 (VDAC) (117). This induces the 
opening of the pores allowing the efflux of pro-apoptotic proteins into the 
cytosol. Whilst Bax and Bak are widely distributed, expression of Bok has 
been found to prevalent in the reproductive tissues. It has been observed to 
translocate to the nucleus (118) and has been suggested to be an essential 
mediator of p53-dependent apoptosis (119), as well as being under the 




Lastly the pro-apoptotic BH3-only proteins as its name suggests, only contains 
the BH3 domain. Its members include BH3 interacting domain death agonist 
(Bid), Bcl-2 interacting mediator (Bim), Bcl-2 antagonist of cell death (Bad), 
Noxa and p53-upregulated mediator of apoptosis (Puma). Their main mode of 
action is to bind to and neutralise their pro-survival relatives (121, 122) or to 























Figure 4: Major Bcl-2 family members 
Bcl-2-family proteins have a crucial role in the regulation of apoptosis through their ability to 
regulate mitochondrial cytochrome c release. The Bcl-2 family comprises three subfamilies 
that contain between one and four BH domains. The anti-apoptotic subfamily comprises 
proteins that contain four BH domains. Most members of this subfamily also contain 
transmembrane domains (TM) and are therefore typically associated with membranes. The 
pro-apoptotic Bax subfamily lacks BH4 domains and promotes apoptosis by forming pores in 
mitochondrial outer membranes. The BH3-only subfamily is a structurally diverse group of 
proteins that only display homology within the small BH3 motif. 










4.4 Mitochondrial-dependent (Intrinsic) Apoptosis 
For a long time, the mitochondria has been considered solely as the organelle 
hosting the Krebs cycle responsible for ATP synthesis. Adding to this role of 
the powerhouse of the cell, the mitochondria has been shown to be a crucial 
component of apoptosis. As its name suggests, the intrinsic apoptotic pathway 
is initiated from within the cell. It can be triggered by DNA damage caused by 
defects in DNA repair mechanisms, treatment with cytotoxic drugs or 
irradiation. In this pathway, activation of caspases is closely linked to 
mitochondrial outer membrane permeabilisation (MOMP). In a non-apoptotic 
cell, pro-apoptotic factors including cytochrome c, AIF (127) and 
Smac/DIABLO (128, 129)  are safely sequestered in the inter-membranal 
space of the mitochondria. However, under an apoptotic trigger, MOMP 
occurs, leading to rapid egress of these factors into the cytosol. Cytosolic 
cytochrome c then associates with apoptotic protease-activating factor-1 
(Apaf-1), promoting its oligomerisation and forming the death signalling 
protein complex, apoptosome (130-132). Procaspase-9 is then recruited to this 
apoptosome and it undergoes autoproteolytic activation. The apoptosome 
activates the downstream effector procaspases-3, -6 and -7 which subsequently 
cleave a specific set of protein substrates, including procaspases themselves. 
This result in the mediation and amplification of the death signal and 
eventually in the execution of cell death with all the morphological and 
biochemical features as describe earlier.  
 
The mechanism by which MOMP occurs involves the formation of pores in 
the mitochondrial membrane. The formation of such pores can be attributed to 
members of the Bcl-2 family as described earlier and/or to the PTPC (133). 
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PTPC is formed at the contact sites between the outer and inner mitochondria 
membranes and have been suggested to play an important role in cytochrome c 
release from the mitochondria. The major components of the PTPC include the 
outer membrane protein (OMP), the adenine nucleotide transporter (ANT) on 
the inner mitochondria membrane as well as VDAC (134, 135). The PTPC 
also includes several other proteins like hexokinase II, mitochondrial creatine 
kinase as well as cyclophillin-D (136), all of which have a role in modulating 
the activity of PTPC. The PTPC usually exists in a closed conformation, 
however, various stimuli such as changes in the mitochondrial membrane 
potential levels, reactive oxygen species (137) and changes in ions 




) (138, 139) are able to induce a 
conformational change to the PTPC, causing it to adopt to an open 
conformation, allowing the entry of water and solutes. This causes the 
mitochondria to swells and eventually causing a physical rupture to the outer 
mitochondria membrane releasing the pro-apoptogenic proteins from within.  
 
4.5 Receptor-mediated (Extrinsic) Apoptosis 
Apoptotic signalling can also occur through the extrinsic pathway mediated by 
members from the TNF ligand and receptor superfamily. When cell surface 
death receptors bind to their specific death ligands (for example those of the 
TNF superfamily), adaptor proteins such as Fas-associated death domain-
containing protein (FADD) are recruited, which in turn mediates the 
recruitment of initiator procaspases such as procaspase-8 via its DEDs to form 
the death-inducing signalling complex (DISC). At the DISC, several 
procaspase-8 molecules are in close proximity to each other and therefore are 
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assumed to activate each other by autoproteolysis. The activated initiator 
caspases then activate effector caspases such as caspase-3 -6 and -7 to effect 
apoptosis (140). 
 
In the extrinsic pathway, cells can be classified into type I cells and type II 
cells. In so called type I cells, independent operation of the receptor-mediated 
pathway is sufficient to evoke apoptosis (141). However, in type II cell, the 
signal coming from the activated receptor does not generate a caspase 
signalling cascade strong enough for execution of cell death on its own. In this 
case, the signal needs to be amplified via mitochondria-dependent apoptotic 
pathway for efficient caspase activation and death execution  (142). It has 
been suggested that the cross-talk between the receptor and mitochondrial 
death pathways is mediated by pro-apoptotic members of the Bcl-2 family, in 
particularly Bax and Bid (143). In a well accepted model, caspase-8 activated 
at the DISC triggers Bid processing. Truncated Bid (tBid) then signals Bax 
translocation from the cytosol to the mitochondrial, where it leads to MOMP, 
egress of pro-apoptotic factors and amplification of the death signal through 
sequential activation of caspase-9 and caspase-3 (144). Overexpression of 
anti-apoptotic protein Bcl-2 can block apoptosis in type II but not in type I 
cells (142, 145). 
 
4.5.1 TNF superfamily ligands and receptors 
The extrinsic apoptosis are induced by extracellular signals (membrane-bound 
or soluble proteins) coming from neighbouring or distant cells. These signals 
are cytokines belonging to the TNF superfamily. They are expressed as type II 
transmembrane proteins (i.e. extracellular COOH-terminal part and cytosolic 
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NH2-terminal part) (146). Proteolysis of their COOH-terminal part by 
metalloproteases allows the release of the cytokines in their soluble forms. 
These ligands have a 20-30% homology in a 150 amino acid domain, known 
as the TNF homology domain (THD), which is responsible for the binding to 
their respective receptors. 
 
TNF superfamily ligands interact with members of the TNF-receptor 
superfamily. The TNF-receptor superfamily currently form a group of about 
29 proteins including TNF-R1 (p55), TNF-R2 (p75), CD40, p75 NGFR, 
TRAMP, Fas (CD95/APO-1), DR4 and DR5. These receptors exist primarily 
as type I transmembrane proteins and are grouped according to the presence of 
conserved cysteine residues in their extracellular ligand binding domain. 
Generally, receptors from this superfamily contain 2 to 6 of such cysteine-rich 
domains (CRDs), each of which is characterised by a region of approximately 
6 cysteine residues that are interspersed within a stretch of 40 amino acids. 
Intra-cysteine disulfide bonds formed between the CRDs of individual subunit 
members promotes the stable formation of a typical functional trimeric or 
multimeric TNF superfamily receptor. The CRDs are also responsible for 
making distinct contacts with its ligand(s) (147).  
 
A subgroup termed the death receptors has been defined from the TNF-
receptor superfamily by virtue of their ability to induce apoptosis and they 
include Fas, TNF-R1, DR4 and DR5. These receptors have in common the 
presence of a conserved intracellular region called death domain, which is a 
protein sequence of about 80 amino acids allowing transmission of cytotoxic 
signal upon ligand binding (147-149). 
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4.5.1.1 TNF and TNF-Receptor 
TNF is known to be able to induce a plethora of signals in cells, which include 
cell activation, proliferation, differentiation as well as apoptosis. TNF is 
observed to bind two receptors, TNF-R1 and TNF-R2. TNF-R1 mediates most 
biological activities of TNF-α including apoptosis, antiviral activity as well as 
activation of nuclear factor-kappaB (NF-ĸB) while TNF-R2 is particularly 
involved in T-lymphocytes (150).  
 
Activation of TNF-R1 by TNF-α leads to the recruitment of TNF-R1-
associated death domain protein (TRADD), through homophillic interaction 
between the death domain (DD) of both proteins, which serves as an adaptor 
molecule allowing for differential signalling to occur via different interactions 
with a range of signalling intermediates, thus mediating various biological 
outcomes (151). For instance, TRADD can recruit FADD and lead to caspase-
8 activation and apoptosis via the extrinsic pathway. However, TNF-α is not 
cytotoxic to most cells because TRADD can recruit TNF-α receptor associated 
factor-2 (TRAF-2) (152) and a serine-threonine kinase RIP to form distinct 
complexes initiating the activation of NF-ĸB and c-Jun-N-terminal Kinase 
(JNK) signalling pathways. It has been well established that activation of NF-
ĸB serves to protect cells against apoptotic stimuli, hence, inhibition of NF-ĸB 
is required for efficient apoptosis induction by TNF-α (153). Additionally, it 
has been shown that induction of NF-ĸB inhibits TNF-α mediated JNK 
activation and that blocking of NF-ĸB results in sustained activation of JNK, 
promoting TNF-α induced apoptosis. Deng et. al. (154) reported that activated 
JNK induces caspase-8 independent cleavage of Bid at a distinct site to 
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generate a cleavage product jBid, leading to the preferential release of 
Smac/DIABLO from mitochondria and subsequently apoptosis. 
 
4.5.1.2 Fas-Ligand and Fas 
Fas was the first member of the TNF receptor superfamily to be associated 
with apoptosis (155). This receptor is widely expressed, predominantly in 
thymocytes and activated T-cells, and abundantly expressed in the liver, heart 
and kidney. Fas upon binding to the Fas-ligand (FasL) trimerises and induces 
apoptosis through its DD which interacts with signalling adaptors like Fas-
associated factor-1 (FAF-1), FADD, FLICE-associated huge (FLASH) and 
RIP. FADD carries a DED and by homologous interaction, it recruits the DED 
containing procaspases-8. This entire complex of proteins is termed DISC and 
allows for cross-activation of procaspases-8/10 due to their induced proximity 
at the DISC (156). Activated caspase-8 can cleave downstream executioner 
caspases like caspase-3 resulting in induction of apoptosis in these cells and 
depending on the type of cells; some might require the involvement of 
mitochondria to amplify the death signal for efficient apoptosis (157).  
 
Fas signalling pathway can be regulated at the level of caspase-8 activation by 
the endogenous inhibitor, FLICE-inhibitory protein (FLIP), which may also be 
recruited by FADD. Interestingly, FLIP may also participate in an alternate 
signalling pathway, recruiting TRAF1, TRAF2, mitogen activated protein 
kinase kinase kinase (MAPKKK), Raf1 and RIP to activate extracellular 
signal-regulated kinase (ERK) and NF-ĸB pathways, leading to proliferation 
and/or inflammation. This differential activity of FLIP, which appears to 
reflect activity of short versus long FLIP isoforms that promote the death 
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versus proliferation pathways, respectively, mediates a major decision in 
response to Fas signalling: death versus proliferation/inflammation (158, 159).  
 
5. TRAIL/APO2L and TRAIL-Receptor 
TRAIL and its cognate receptors were characterised more than a decade ago, 
generating immense interest with regards to its distinctive ability to induce 
tumour specific cell death, without affecting normal cells. In this section, a 
greater detail of the cytokine will be provided. 
 
5.1 TRAIL 
TRAIL was identified by two independent groups based on its sequence 
homology with FasL and TNF-α. It displays a 28% amino acid sequence 
identity to FasL and 23% identity with TNF-α (160). In humans, the gene that 
encodes for TRAIL is located at chromosome 3q26. The genomic structure of 
the TRAIL gene spans approximately 20kb and is composed of five exon and 
four introns. TRAIL is composed of 281 amino acids and has characteristics of 
a type II transmembrane protein whereby the COOH-terminus with the 
receptor-binding domain lies extracellularly. Its extracellular domain can be 
cleaved by cysteine protease to give a biologically active soluble form of the 
ligand. In contrast to other members in the TNF super family of ligands whose 
expressions are tightly regulated and only transiently expressed on activated 
cells, mRNA of TRAIL is detected in a wide variety of tissues including 
peripheral blood mononuclear cell, spleen, thymus, prostate, ovary, small 
intestine, colon and placenta but not the liver, testis or brain (161). As with 
most other members of the TNF superfamily, TRAIL forms a homotrimer that 
binds to three receptor molecules. Both cell-bound and soluble TRAIL is able 
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to induce apoptosis through the classical receptor-mediated pathway, namely 
via DISC formation (with FADD as the adapter) and activation of initiator 
caspases-8 and -10 which in turn activates downstream executioner caspases. 
Typical of other TNF superfamily ligands, TRAIL-induced apoptosis in Type 
II cells involves a cross-talk between the intrinsic and extrinsic apoptotic 
pathways which is mediated by Bid. 
 
5.2 TRAIL receptors 
TRAIL can bind to several distinct receptors. To date, five receptors that bind 
to TRAIL have been identified (Fig 5). The first four receptors, DR4, DR5, 
decoy receptor 1 (DcR1) and decoy receptor 2 (DcR2), are closely related cell-
bound members of the TNF-receptor superfamily (162). The fifth receptor 
osteoprotegerin (OPG) is a soluble member of the TNF-receptor superfamily. 
It binds weakly to TRAIL at physiological temperature (37°C) (163).  
 
DR4 and DR5 are type I transmembrane protein comprising of 468 amino 
acids and 411 amino acids respectively. They contain two extracellular 
cysteine-rich motifs. Their cytoplasmic domain contains a DD that is similar 
to that found in TNF-R1 and Fas. The expression pattern of both receptors are 
as widespread as TRAIL, but has also been detected in liver, testis and brain 
(148). Both DR4 and DR5 were capable of eliciting cell death upon TRAIL 
binding due to the presence of intracellular DD. 
 
In contrast, DcR1 and DcR2, lacks and contains truncated DD respectively. 
Neither of them can transduce an apoptotic signal and they may act instead as 
antagonistic “decoy” receptors (164, 165). DcR1 is a 299 amino acid protein 
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lacking a cytoplasmic segment, and instead remains bound to the cell via a 
glycosylphosphatidylinositol linker. The expression of DcR1 is limited 
compared to other TRAIL receptors and while overexpression of this receptor 
confers protection against TRAIL-induced apoptosis, removal of DcR1 from 
the cell surface by phosphatidylinositol phospholipase C sensitises cells to the 
cytotoxic effects of TRAIL. DcR2 on the other hand has the same widespread 
expression as DR4 and DR5 and was also found to confer protection against 
TRAIL-induced death. Overexpression of DcR2 in a TRAIL sensitive cell line 
rendered these cells resistant to the apoptotic trigger of TRAIL. However, no 
direct correlation between the sensitivities of cells to TRAIL and the 
expression pattern of either DR4/5 or DcR1/DcR2 has been established. 
 
The fifth and last receptor for TRAIL, OPG, acts mainly as a regulator of the 
development and activation of osteoclasts in bone remodelling. This activity 
is, however, not due to its interaction with TRAIL. The higher affinity ligand 
for OPG is the TNF-like cytokine receptor activator of NF-ĸB-ligand 
(RANKL) which also binds to the receptor activator of NF-ĸB (RANK) (166). 
Nonetheless, OPG is still able to bind TRAIL, albeit at a lower affinity 
compared to other TRAIL-receptors. There is mounting evidence to suggest 
OPG can act in a paracrine or autocrine manner by binding TRAIL and 
promoting the survival of prostate cancer and multiple myeloma cells (167). It 
was also observed to promote survival of microvascular-endothelial cells, 
though the role of TRAIL in this has not been confirmed. Nevertheless, it is 
likely that the role of OPG as a survival factor is highly dependent on the 
relative concentrations, the timing, location and expression pattern of TRAIL 
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and OPG in the microenvironment. In summary, more work remains to be 














Figure 5: TRAIL receptors  












































5.3 TRAIL as a “tumour suppressor” 
A role for TRAIL in host immunosurveillance against primary tumour 
development has been described. Neutralisation of TRAIL promoted tumour 
development in mice inoculated with carcinogen methylcholanthrene (MCA). 
The increased tumour promoting effect of MCA was also observed in TRAIL-
/- mice (169). Moreover, the emergence of TRAIL sensitive fibrosarcoma cells 
in TRAIL-/- and IFN-deficient mice implies an immune selection pressure 
against TRAIL sensitive cells during tumour development (170). Lymphoid 
malignancies have been reported to develop in more than 25% of TRAIL-/- 
mice after 500 days of life. Tumours need to develop and gain metastatic 
potential by acquiring resistance to TRAIL if this ligand is involved in 
immune surveillance against human tumour metastases. Indeed, allelic losses 
of chromosomal segments encoding both DR4 and DR5 have been observed in 
several cancers, including non-Hodgkin’s lymphoma and lung, breast, colon, 
prostate, hepatocellular and head and neck cancers, suggesting their tumour 
suppressive role (171, 172). 
 
5.4 TRAIL as potential chemotherapeutic agent 
Despite continuous efforts to improve conventional cancer treatments, the 
long-term outcome for many patients treated with surgery, chemotherapy, 
and/or radiotherapy remains suboptimal. Furthermore, the lack of specificity 
of these approaches may cause significant toxicity. Therefore there is an 
urgent need for novel and effective therapies against cancer. Ligation of death 
receptors to induce apoptosis in tumour cells has been proposed as a viable 
method of treating cancers. Unfortunately, although the FasL and TNF-α have 
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shown efficacy in killing cancer cell, the systemic administration have led to 
life-threatening toxicity in vivo (173, 174). Consequently, FasL and TNF-α 
have been considered unsuitable for chemotherapeutic purposes.  
 
During the last decade, TRAIL has received particular attention as a potential 
tumour specific cancer therapeutic because it selectively induces apoptosis in a 
wide variety of transformed cells in vitro (161, 175) and most importantly, in 
vivo (173, 174) with no toxicity to normal cells. Song et. al. showed that in 
mice transplanted with hematopoietic cells overexpressing mouse TRAIL, the 
syngeneic grafts of carcinoma cells had a decreased tumoural growth rate and 
it was also observed that those tumour cells were undergoing TRAIL-mediated 
apoptosis while normal cells were left intact (176). The potential of TRAIL 
therapy was further supported in immunodeficient mice bearing human 
tumour xenografts, where TRAIL treatment substantially inhibited tumour 
progression in a variety of human tumours including breast and colon 
carcinomas, gliomas and multiple myelomas (161, 177). TRAIL was also 
effective at inducing apoptosis in primary tumour samples from patients with 
multiple myeloma, colon carcinoma and pancreatic adenocarcinoma grown in 
immunodeficient mice (178-180). 
 
Although TRAIL has been very promising as a chemotherapeutic agent, one 
major impediment for the use of this agent in cancer therapy is that many 
cancer cells are developing resistance to TRAIL (181, 182). However, the 
interest in TRAIL as a therapeutic agent has not been diminished. The 
growing understanding of TRAIL signalling, particularly the focus on 
apoptotic blocks responsible for resistance, has brought to light the possibility 
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of certain known drugs or molecules such as 5-Fluorouracil, Cisplatin, 
Etoposide, LY294002 or LY303511 (179, 183-185) to restore tumour cells’ 
sensitivity to TRAIL. Indeed, this combinatorial treatment were able to restore 
tumour cells’ sensitivity to TRAIL-mediated apoptosis, with no toxicity to 
normal cells. It also has the added benefit of lowering the amount of the 
combinatorial drug used, hence reducing its potential side-effects. 
 
5.5 TRAIL resistance in cancer 
While many reports have proven TRAIL to be a potent inducer of apoptosis in 
a wide variety of human and mouse tumour cell lines, many primary tumours 
are resistant to TRAIL-induced apoptosis and several mechanisms underlying 
TRAIL resistance have been proposed.  
 
At the receptor level, interaction of TRAIL with its cognate receptors DR4 and 
DR5 triggers the transduction of TRAIL-induced apoptotic signalling via the 
formation of DISC, allowing for activation of the downstream death executors, 
caspases.  Hence, any changes with regards to the protein/surface expression 
of TRAIL receptors, or to the components of the DISC has a profound effect 
on the ability of TRAIL to function efficiently as a death inducing ligand. The 
level of TRAIL receptors present on tumour cell surface is an apparent 
regulator of TRAIL-induced apoptosis. A lack of expression of TRAIL DR4 
due to epigenetic silencing correlated with resistance to TRAIL-induced 
apoptosis in ovarian cancer cells (186, 187). Similarly, deficient surface 
transport leading to reduced surface DR4 increases resistance of colon cancer 
cells to TRAIL (188). Mutations resulting in loss-of-function DR4 and DR5 
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have also been observed in head and neck squamous, breast cancer cells and 
non-Hodgkin's lymphoma (171, 172, 189-191).  
 
In addition, resistance of cells to TRAIL can also be due to the up-regulation 
of decoy receptors DcR1 and DcR2, or rather, the increased ratio of decoy 
receptors to death receptors. Decoy receptors have been shown to abolish 
TRAIL-induced apoptosis by competing with DR4 and DR5 for the binding to 
TRAIL. Study demonstrated that that DcR1 seems to be overexpressed in 
many primary tumours of the gastrointestinal tract (192). Also, Sanlioglu et. 
al. reported that DcR2 expression correlated with TRAIL resistance in human 
breast tumor cell lines (193). Further studies from this group demonstrated that 
modulating TRAIL receptor expression, especially DcR2, on human lung and 
prostate tumor cells using small interfering RNA improved the tumouricidal 
activity of TRAIL (194-196). (196) 
 
Another option for explaining the differences in tumour cell sensitivity to 
TRAIL-induced apoptosis  involves the differential expression of any of a 
number of pro- and anti-apoptotic proteins within the tumor cell that 
collectively help to regulate the signals generated from trimerised DR4 and 
DR5. Molecules such as cellular FLICE-like inhibitory protein (cFLIP), Bcl-2 
family members, inhibitor of apoptosis proteins, the extracellular signal-
regulated kinases survival pathway, Akt, and Toso, have all been implicated in 
regulating the TRAIL receptor signal transduction pathway (145, 197-202). At 
the level of the DISC, cFLIP inhibits caspase activation by competing for 
binding to FADD, thus acting as an important anti-apoptotic factor. 
Suppression of cFLIP can be sufficient to sensitize some cancer cells to 
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TRAIL-induced apoptosis (203, 204). High levels of XIAP expression have 
been observed in many tumour cell lines and may lead to TRAIL resistance by 
directly inhibiting caspases-3, -7 and -9, even in the presence of Smac/Diablo 
(205). Overexpression of anti-apoptotic members of the Bcl-2 family, such as 
Bcl-2 and Bcl-XL, has also been shown to cause TRAIL resistance in type II 
cells (206). In addition, the anti-apoptotic Bcl-2 member, Mcl-1, can inhibit 
pro-apoptotic Bcl-2 family proteins such as Bid and its overexpression also 
confers resistance to TRAIL-mediated apoptosis in vitro (207). Interestingly, a 
recent report has suggested that some cancer cells may simultaneously exhibit 
more than one mechanism of resistance (208). 
 
5.6 Restoring cancer cell sensitivity to TRAIL 
Tumour cells engage a variety of mechanisms to evade TRAIL-induced 
apoptosis as described earlier. It results in either a moderate or complete 
resistance to this death-inducing ligand.  Identifying such underlying 
mechanisms of resistance provides a rational approach towards the design of 
novel compounds, or a complementation with existing therapies, that serve to 
re-sensitise such resistant tumour cells to TRAIL. Knowledge of the root cause 
of resistance in a particular tumour setting and efforts in thwarting its effects 
would allow for successful implementation of TRAIL as an anti-tumour agent. 
Interestingly and fortunately,  it has been observed in a number of studies that 
treatment of resistant cells with either TRAIL or subtoxic doses of the 
sensitising drug has minimal effect on cell viability, yet, they produce marked 
synergistic effect when used in combination. The crux of the matter lies in 
providing, or enhancing, a pro-apoptotic environment for a more effective 
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death stimuli transduction upon TRAIL ligation to its receptors, or in 
dampening the dominant pro-survival/anti-apoptotic mileu within the resistant 
tumour cells that is achieved upon application of another drug in combination 
with TRAIL. As such, the measures initiated for re-sensitising tumour cells to 
TRAIL can be broadly classified into several groups; mainly 
drugs/compounds that has an effect on the death receptors, the proteins 
involved in the induction of mitochondrial-dependent apoptosis or major 
proteins involved in the execution of apoptosis.  
 
5.7 Pre-clinical and clinical evaluation of TRAIL 
5.7.1 Pre-clinical studies 
The majority of the studies published since the initial report describing TRAIL 
have been on the in vitro and in vivo tumouricidal activity of TRAIL. In these 
preclinical trials, recombinant human TRAIL (rhTRAIL) has induced 
apoptosis in multiple malignant cell lines, derived from both solid and 
hematologic malignancies, either alone or in combination with various 
chemotherapy agents or radiation (174, 209-212). However, the 
implementation of recombinant TRAIL as a therapeutic agent has been 
initially hampered by the unexpected warning concerns arose when numerous 
preclinical studies using different forms of recombinant TRAIL showed 
varying  levels of toxicity in several  model systems of normal human cells 
such as primary astrocytes, hepatocytes, keratinocytes and prostate epithelial 
cells in vitro (173, 181, 213-215).  But, it was soon clarified that these studies 
utilised highly aggregated recombinant forms of TRAIL (175, 216, 217), for 
example His-TRAIL or cross-linked FLAG-TRAIL, which had tendencies to 
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form insoluble aggregates that leads to high-order multimerisation of death 
receptors. This potentiated the antitumor efficacy of these TRAIL preparations 
but also increases their toxicity to normal cells (218-220).   
 
Although TRAIL can induce apoptosis in a variety of tumour cell, 
overexpression of decoy receptors has been suggested to confer TRAIL 
resistance to primary tumour cells. Utilising agonistic antibodies against the 
death receptors present a more viable solution to such an issue. The potential 
of this approach are the specific binding, as well as high affinity, of antibodies 
to the intended receptors and the longer in vivo half-life of these agonistics 
compared to that of rhTRAIL As a result, agonistic antibodies targeting DR4 
and DR5 have been generated by several groups (221-224) and they have 
observed apoptosis in a broad range of tumour cell lines as well as tumour 
regression in vitro and in vivo using immunodeficient mice xenografted with  
a variety of human tumours (224-226). 
 
Apart from the use of rhTRAIL and agonistic antibodies as monotherapy, 
combinatorial treatment with traditional chemotherapies, as well as with novel 
compounds targeting proteins involved in the TRAIL signalling pathway, are 
under development. A variety of anticancer agents used in combination with 
TRAIL have shown promising result in the preclinical trials. The proteasome 
inhibitor bortezomib, approved for the treatment of multiple myeloma, appears 
to have a pro-apoptotic effect by inhibiting ubiquitin-mediated degradation of 
pro-apoptotic proteins, increasing p53 and DR5 expression and decreasing 
cFLIP expression (227-230). Bortezomib have been shown to sensitises some 
cell lines derived from breast, colon and kidney tumours to TRAIL-mediated 
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apoptosis (231). More recently, Bortezomib has been shown to sensitise 
resistant non-small cell lung cancer cell lines to apoptosis induced by agonist 
monoclonal antibodies to DR4 and DR5 (232). The kinase inhibitor Sorafenib 
has been shown to down-regulate Bcl-XL, Mcl-1 and cFLIP and to potentiate 
TRAIL-induced cell death in several human leukemia cell lines but not in 
normal CD34+ bone marrow cells (233). Histone deacetylase inhibitors are a 
new class of antitumor drugs that influence gene expression by promoting 
acetylation of histones (234) and have been found to up-regulate DR5 and 
sensitise various tumour cells to TRAIL-induced apoptosis (235-238). 
 
5.7.2 Clinical trials 
Translation of the preclinical observations of rhTRAIL or agonistic anti-
TRAIL receptor monoclonal antibodies into the clinical realm has begun in 
recent years. A phase Ia trial of rhTRAIL consisting of a dose escalation to 15 
mg/kg for patients with advanced solid tumours or non-Hodgkin's lymphoma 
has yielded encouraging results with no attributable toxicities (239). Of the 32 
patients evaluated, 17 (53%) had stable disease, 13 (41%) had progression and 
one patient with chondrosarcoma had a confirmed partial response. 
Preliminary results of a phase Ib trial of rhTRAIL in combination with 
rituximab in patients who have progressed after treatment for low-grade non-
Hodgkin lymphoma have recently been reported (240). There were no dose-
limiting toxicities or serious adverse events at doses of 4 and 8mg/kg, and of 
the 5 patients assessed, 2 had stable disease, 1 had a partial response and 2 had 




Clinical trials of agonistic anti-DR4 and DR5 monoclonal antibodies are also 
underway. In a phase I study of the DR4  agonist, Mapatumumab, 49 patients 
with advanced solid malignancies safely received doses of up to 10mg/kg 
every 14 days (241). The mean half-life of the antibody was 18 days. Nineteen 
patients had stable disease, with 2 instances lasting 9 months, but 2 patients 
did have elevated liver function tests probably related to Mapatumumab 
administration. A phase Ib study of Mapatumumab given to patients with 
advances malignancies in combination with paclitaxel and carboplatin 
achieved a partial response in 4/28 patients (242). In another phase Ib study of 
Mapatumumab with gemcitabine and Cisplatin given to patients with 
advanced solid malignancies, doses as high as 30mg/kg every 3 weeks were 
safe with 9/45 patients achieving a partial response and 13/45 patients 
experiencing stable disease after 6 cycles (243). A phase II trial of 
Mapatumumab as a single agent was carried out in 32 previously treated 
patients with advanced non-small cell lung cancer. At a dose of 10mg/kg 
given every 21 days, the antibody was well-tolerated and 9/32 patients had 
stable disease; however, none of the patients showed a response based on the 
Response Evaluation Criteria in Solid Tumors (RECIST) criteria (244). 
 
A phase I trial of Lextumumab, a DR5 agonistic antibody was carried out in 
patients with advanced solid malignancies.  A dose of 10mg/kg was given 
every 21 days, the maximum tolerated dose (245). The half-life of this 
antibody was 16 days and 12 out of 37 patients had stable disease lasting a 
median of 4.5 months. Lexatumumab has also been evaluated in combination 
with Gemcitabine, Premetrexed, Doxorubicin and FOLFIRI (Leucovorin, 5-
Fluorouracil and Irinotecan) in a phase 1b study (246). In this combination 
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study, Lexatumumab was well tolerated at 10mg/kg with 3/41 patients 
experiencing a confirmed partial response. 
 
Apomab, another DR5 agonistic antibody has undergone a phase I trial in 
patients with advanced, treatment-refractory solid tumour (247). Doses up to 
20mg/kg given every 14 days were well tolerated. This antibody's half-life 
was 15-20 days and no human anti-human antibodies were detected. There 
were no objective responses observed, but 1 patient with appendiceal cancer 
had stable disease and 1 patient with colorectal cancer had symptomatic 
improvement and shrinkage of target lesions. 
 
TRAIL remains a promising biologically-targeted anti-cancer therapy that is 
currently in phase II clinical trials. TRAIL monotherapy may prove useful for 
those tumours that exhibit TRAIL sensitivity. However, research over the last 
decade has exposed the complexity of TRAIL signalling and a myriad of 
resistance mechanisms to TRAIL-induced killing that are present in many 
human tumour cells. Combination treatments to sensitise these cells to TRAIL 
are now the subject of new clinical trials. 
 
6. Reactive nitrogen species - Peroxynitrite 
Reactive nitrogen species include nitric oxide (·NO), peroxynitrite (ONOO
−
) 
and nitrogen dioxide radical (NO2·). Peroxynitrite is a reactive oxidant, 
produced from nitric oxide (·NO) and superoxide anion (O2
·–
). It reacts with a 
variety of biological macromolecules. It is produced in the body in response to 
physiological stress and environmental toxins. It is a potent trigger of 
oxidative protein and DNA damage. It can cause energy depletion, apoptosis 
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and necrosis of cells. Peroxynitrite generation is a crucial pathological 
mechanism in stroke, diabetes, inflammation, neurodegeneration and cancer. 
 
6.1 Formation of peroxynitrite 
Peroxynitrite is a strong biological oxidant and nitrating compound formed 
from the extremely rapid, diffusion limited (rate constant k between 6.6 and 19 
× 10
9M−1sec−1) reaction between the superoxide anion and nitric oxide (248). 
The rate of this reaction is at least 3–8 times greater than the rate of 
superoxide anion decomposition by superoxide dismutase (SOD, k = 2.5 × 
10
9M−1sec−1). This indicates that nitric oxide has the ability to drive 
superoxide anion away from its main detoxification pathway (248). The 
cellular sources of nitric oxide are restricted to the various isoforms of nitric 
oxide synthases, whereas superoxide anion can arise from the mitochondrial 
electron transport chain, NADPH oxidase and xanthine oxidase (248, 249). 
Importantly, the reaction of nitric oxide with superoxide anion essentially 
depends on the ratio of superoxide to nitric oxide rather than the net amount of 
these two precursors. This imply that peroxynitrite is generated whenever 
approximately equal, but not necessarily augmented, fluxes of nitric oxide and 
superoxide anion are present (248). 
 
6.2 Reactivity of peroxynitrite 
Peroxynitrite easily crosses biological membranes and despite its short half-
life (~10 ms), it can interact with target molecules in adjacent cells within one 
or two cell diameters (248, 249). It exhibits unique chemical reactivities such 
as protein nitration, lipid peroxidation, DNA strand breakage and base 
modification, which may have cytotoxic effects leading to mutagenesis. 
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Peroxynitrite is thought to be involved in both cell death and an increased 
cancer risk (250-252).  
 
The reaction of peroxynitrite with lipids leads to peroxidation 
(malondialdehyde and conjugated diene formation) and formation of nitrito-, 
nitro-, nitrosoperoxo-, and nitrated lipid oxidation derivatives (253-255).  
 
Peroxynitrite is a particularly effective oxidant of aromatic molecules, 
thioethers and organosulfur compounds that include free amino acids and 
polypeptide residues. The reaction of various amino acids with peroxynitrite 
leads to the conversion of cysteine and glutathione to disulfides; methionine 
being converted to sulfoxide or is fragmented to ethylene and dimethyl 
disulfides, which is then oxidised to formaldehyde; and tyrosine and 
tryptophan undergoing one electron oxidation to radical cations, which are 
hydroxylated, nitrated and dimerised (256, 257).  
 
Exposure of amino acids, peptides and proteins to peroxynitrite in the presence 
of oxygen gives rise to hydroperoxides. These hydroperoxides decompose to 
oxygen and carbon centered radicals on exposure to copper (Cu
+
) and other 
transition metal ions. Hydroperoxide formation on nuclear proteins results in 
oxidative damage to associated DNA. These hydroperoxide-derived radicals 
react readily with pyrimidine DNA bases and nucleosides to form adduct 
species, for example 8-oxo-dG. This adduct is highly mutagenic and induces 
G:C to T:A transversions in human DNA after replication (258). 
 
Purine nucleotides are vulnerable to oxidation and adduct formation (259, 
260). Peroxynitrite is a mutagenic agent with a potential to produce nitration, 
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nitrosation and deamination of DNA bases. Methylation of cytosine in DNA is 
important for the regulation of gene expression and normal methylation 
patterns are altered by the carcinogenic effect of peroxynitrite (261). 
Prominent DNA modifications induced by peroxynitrite include the formation 
of 8-nitro-guanine and 8-oxyguanine, as well as the induction of single strand 
breaks (262, 263). DNA single strand breaks generated by peroxynitrite leads 
to activation of the nuclear enzyme, poly (ADP-ribose) synthetase (PARS), 
which can trigger cellular suicidal pathway. Single strand breaks generated by 
peroxynitrite can arise from two processes: 1) sugar damage, which involves 
abstraction of hydrogen leading to the formation of sugar radical or 2) base 
damage, which rapidly depurinates to generate abasic sites (262). Peroxynitrite 
is mutagenic in the supF gene inducing G to T transversions and deletions 
clustered at the 5’ end of the gene. The mutagenicity of peroxynitrite is 
believed to result from chemical modifications at guanine leading to 
miscoding (264). 
 
Carcinogenesis is induced by altered DNA or tissue damage, mutations and 
chromosomal aberrations (265, 266). Peroxynitrite is a mutagenic agent with 
the potential to produce nitration, nitrosation and deamination reactions on 
DNA bases. It reacts significantly only with guanine, which upon oxidation 
and nitration leads to mutagenicity and strand breaks, respectively (267, 268). 
Peroxynitrite levels are elevated in inflammation and infection and play an 
important role in carcinogenesis. It damages tumour suppressor genes and 
leads to the expression of proto-oncogenes. Peroxynitrite induced DNA 




6.3 Cytotoxicity of peroxynitrite 
Peroxynitrite if formed in sufficient amounts to overcome cellular antioxidant 
defences, it will inflict various oxidative damage to proteins, lipids and DNA. 
These alterations will inactivate metabolic enzymes, ionic pumps, structural 
proteins, disrupt cell membranes and break nucleic acids, resulting in the 
dysfunction of multiple cellular processes and the induction of cell death 
through both apoptosis and necrosis, depending on the level of peroxynitrite 
(248, 249).  
 
Peroxynitrite is capable of oxidizing protein and non-protein sulfhydryl (-SH) 
groups including lipid peroxidation, and reactivity with aromatic amino acid 
side chain in proteins to form nitroadducts (270). Peroxynitrite induced 
tyrosine nitration may lead to dysfunction of nitrated proteins, superoxide 
dismutase (SOD), cytoskeletal proteins, neuronal tyrosine hydroxylase, 
cytochrome P450 and prostacyclin synthase (271-274). Oxidation of critical -
SH groups is responsible for the inhibition of mitochondrial and cytosolic 
aconitase and other critical enzymes in the mitochondrial respiratory chain 
(275). 
 
Peroxynitrite is also able to inhibit a variety of ion-pumps including calcium 





activity resulting in global dysregulation of ion-balance (276). Peroxynitrite 
mediated oxidation of catecholamines contribute to a variety of central 
nervous system and cardiovascular pathologies (277).  
 
Peroxynitrite mediates both oxidative and deaminative DNA injury (278). 
DNA single strand breakage, initiated by endogenous or exogenous 
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peroxynitrite, is a potent trigger of PARP activation, which is a major 
contributor of programmed cell death and necrosis under conditions of severe 
oxidative stress (279-282). Peroxynitrite generation and consequent PARP 
activation is known to play an important role in many diseases such as 
diabetes, cardiac failure, ischemia/reperfusion and inflammation (283, 284).  
 
In addition, peroxynitrite can affect signalling pathways by nitration as well as 
by oxidation. While nitration of tyrosine residues by peroxynitrite modulates 
signalling processes relying on tyrosine phosphorylation and 
dephosphorylation, oxidation of phosphotyrosine phosphatases may lead to an 
alteration in the tyrosine phosphorylation/dephosphorylation balance (285). 
Peroxynitrite, being a terminal mediator of cell injury, also enhances and 
triggers a variety of pro-inflammatory processes. It mediates the cytokine 
induced interleukin-8 (IL-8) expression in human leukocytes. These 
alterations can culminate in a dysregulation of cellular signal transduction 
pathways (286, 287). 
 
6.4 Peroxynitrite-induced cell death 
The mechanism by which peroxynitrite induces cell death is not fully 
understood. However, it is becoming clearer with studies on its toxicology, 
physiology and biochemistry. It was shown for the first time by Whiteman et 
al., (288) that peroxynitrite induces mitochondrial dysfunction in cells via a 
calcium-dependent process that leads to caspase-independent apoptosis 
mediated by calpains. The mode of cell death induced by peroxynitrite can be 
necrosis, apoptosis or mixed types of cell death, depending on the 
peroxynitrite concentration, duration of peroxynitrite exposure and the 
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intracellular ATP levels (289-291). Activation of PARP by damaged DNA is 
suggested to be a major cause of peroxynitrite induced necrosis (292). 
 
Peroxynitrite toxicity is a major cause of neuronal injury in stroke and 
neurodegenerative disorders and the mechanism involved remains a critical 
area of investigation (293).  
 
Peroxynitrite induces DNA fragmentation and apoptosis in a number of cell 
types, including pheochromocytomaderived PC12 cells, cortical neurons, HL-
60 cells and rat thymocytes. Shacka et. al. (294) has reported that peroxynitrite 
activation of the intrinsic apoptotic pathway in PC12 cells is preceded by 
phosphorylation of p38 and JNK, mitogen activated protein kinases (MAPK), 
and translocation of phosphorylated JNK to the mitochondria. Furthermore, 
they show that the inactivation of the phosphatidylinositol 3-kinase 
(PI3K)/PKB pathway is important in peroxynitrite-induced apoptosis. When 
isolated mitochondria are treated with peroxynitrite the permeability transition 
pore (MTP) is activated and cytochrome c is released, suggesting that 
peroxynitrite-induced apoptosis may be the result of direct oxidative damage 
to the mitochondria. Treatment with peroxynitrite also decreases the activity 
of the PI3K pathway, while stimulating the activity of p38 and JNK mitogen-
activated protein kinase pathways. Both the inactivation of PI3K and the 
activation of p38 and JNK/MAPK have been shown to promote apoptosis. 
Furthermore, activation of PI3K is important in preventing apoptotic 
signalling in PC12 cells. These observations suggest that peroxynitrite-
induced cell death might result from the activation of specific apoptotic 




As mention in the earlier section, TRAIL has received particular attention as a 
potential tumour specific cancer therapy because it selectively induces 
apoptosis in a wide variety of transformed cells in vitro as well as in vivo, with 
no toxicity to normal cells. Currently, TRAIL is already in phase I/II clinical 
trials for pancreatic cancer, lymphoma, lung cancer and myeloma, but it has 
not been shown in NPC. Therefore it would be of interest to look at the 
potential of TRAIL as a NPC therapy. This project aims to: 
 
1. To test the potential of TRAIL as a novel therapy for NPC using NPC 
cell lines, HK-1 and C666-1. 


















MATERIAL AND METHODS 
 
Cell line 
The human nasopharyngeal carcinoma cell lines HK-1 and C666-1 were 
generously provided by Dr. Wenson (National University of Singapore). They 
are maintained
 
in Roswell Park Memorial Institute medium 1640 (RPMI 1640, 
Hyclone Logan, Utah, USA) supplemented with 1% L-glutamine, 1% 
streptomycin-penicillin and 10% FBS. All cell lines used were grown and 
passaged in a humidified incubator at 37°C with 5% CO2. 
 
Antibodies 
For western blotting 
From Cell Signalling Technology, Inc. Danvers, MA: 
Mouse monoclonal Anti-Cytochrome C  
Mouse monoclonal Anti-Bid  
Mouse monoclonal Anti-CuZnSOD  
Mouse monoclonal Anti-Caspase-3  
Mouse monoclonal Anti-Caspase-8  
Rabbit polyclonal Anti-Caspase-9  
From Santa Cruz Biotechnologies, Santa Cruz, CA, USA: 
Mouse monoclonal anti-VDAC  
Mouse monoclonal anti-Bcl2  
Mouse monoclonal Anti-β-Actin  
Rabbit polyclonal GAPDH  
Rabbit polyclonal Anti-DR4  
Goat polyclonal Anti-DR5  
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From Origene, Rockville, MD: 
Mouse monoclonal anti-DDK  
From BD Biosciences, USA: 
Rabbit polyclonal Anti-MnSOD 
From Aviva System Biology, CA, USA: 
Rabbit polyclonal Anti-TMTC2  
From Abcam, Cambridge, UK: 
Rabbit polyclonal Anti-Caveolin 
Goat polyclonal Anti-Flotillin  
From Pierce Chemical Co. Rockford, IL, USA: 
Goat Anti-mouse IgG HRP conjugated secondary antibody  
Goat Anti-Rabbit IgG HRP conjugated secondary antibody  
Rabbit Anti-Goat IgG HRP conjugated secondary antibody  
 
For flow and confocal analysis 
From R&D systems, Inc Minneapolis, MN, USA: 
Anti-human TRAIL-R1 (TNFRSF10A/DR4)-Phycoerythrin  
Anti-human TRAIL-R2 (TNFRSF10B/DR5)-Phycoerythrin  
From Invitrogen, Eugene, Oregon, USA  
Alexa Fluor-568 Goat Anti-rabbit IgG  
Alexa Fluor-488 Rabbit Anti-mouse IgG  
 
Reagents and chemicals  
The pan-caspase inhibitor, ZVAD-fmk was obtained from Alexis 
Biochemicals, Lausen, Switzerland. The Superfect transfection reagent was 
obtained from Qiagen, Hilden, Germany and the Dharmafect transfection 
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reagent was obtained from Thermo Scientific, MA. Sucrose, HEPES, 
Propidium iodide (PI), Crystal violet, Bromophenol blue, DMSO, Tween 20, 
EDTA, DTT, Tris and Glycine were purchased from Sigma Aldrich, St. Louis, 
MO. TRAIL was purchased from Biomol, Plymouth Meeting, PA, USA. The 
CM-H2DCFDA molecular probe and Fluorogenic substrates of caspase-8, -9 
and -3 were from Invitrogen, Eugene, Oregon, USA. The Iron porphyrinate 
(FeTPPS) was purchased from Merck, Darmstadt, Germany and Peroxynitrite 
from Cayman, USA. The Coomassie blue reagent was obtained from Pierce 
Biotechnology (Rockford, IL, USA). 10X phosphate buffered saline (PBS), 
10X SDS, Tris-HCl buffer (pH 7.4) were purchased from NUMI Media 
Preperation Facility (National University of Singapore). 
 
Plasmids and siRNAs 
The plasmid pcDNA-Bcl-2 containing the full-length human Bcl-2 gene was a 
generous gift from Dr. Elizabeth Yang (Vanderbilt University, USA). The 
pcDNA3.1 empty vector was obtained from Invitrogen (Invitrogen, Carlsbad, 
CA). The pCMV6 empty vector and the pCMV6-Myc-DDK-TMTC2 plasmid 
containing the full-length human TMTC2 gene were obtained from Origene 
(Origene, Rockville, MD). siRNAs for DR4 and DR5 as well as the scrambled 
siRNA were obtained from Dharmacon Technologies (Thermo Scientific, 
MA). siRNAs for caspase-3 and caspase-8 were obtained from Qiagen 
(Qiagen, Hilden, Germany).  siRNAs for TMTC2 was obtained from 






Transient transfection of plasmids 





 cells/well respectively for a 12-well tissue 
culture plate the day before) were transfected with 2µg of pcDNA-Bcl-2 or 
pcDNA3.1 using the Superfect transfection reagent (Qiagen) (Refer to the 
transfection manual provided by the supplier for the protocol). Cells were 
cultured for 24hr after transfection before any subsequent experiments.  
 
For transient overexpression expression of TMTC2 protein, HK-1 and C666-1 




 cells/well respectively for a 6-
well tissue culture plate the day before) were transfected with 4µg of pCMV6-
Myc-DDK-TMTC2 or pCMV6 using the Superfect transfection reagent 
(Qiagen) (Refer to the transfection manual provided by the supplier for the 
protocol). Cells were cultured for 48hr after transfection before any 
subsequent experiments.  
 
Transient knock-down of protein expression 
For knock-down of DR4 and DR5 gene expression, 100nM of DR4 siRNA or 
50nM of DR5 siRNA or scrambled siRNA was transfected into cells using the 
Dharmafect 1 transfection reagent (Dharmacon) (Refer to the transfection 
manual provided by the supplier for the protocol). Cells were cultured for 24hr 
for DR5 knock-down and 48hr for DR4 knock-down before subsequent 
experiments. 
 
For knock-down of caspase-3 and caspase-8 gene expression, 50nM of siRNA 
(caspase-3 siRNA or caspase-8 siRNA or scrambled siRNA) was transfected 
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into cells using the Dharmafect 1 transfection reagent (Dharmacon) (Refer to 
the transfection manual provided by the supplier for the protocol). Cells were 
cultured for 24hr before subsequent experiments. 
 
For knock-down of TMTC2 gene expression, 50nM of TMTC2 siRNA or 
scrambled siRNA was transfected into cells using the Dharmafect 1 
transfection reagent (Dharmacon) (Refer to the transfection manual provided 
by the supplier for the protocol). Cells were cultured for 48hr before 
subsequent experiments. 
 
Cell viability assay 
In a typical survival assay, HK-1 (0.1x10
6
 cells/well) and C666-1 (0.2x10
6
 
cells/well) cells were plated in a 24-well tissue culture plate (2 days prior 
treatment). They were then treated with 25ng/ml to 100ng/ml of TRAIL 
depending on the experiment for a period of 24hr. Cytotoxicity was 
determined by the crystal violet assay. After drug exposure, cells were washed 
once with 1X PBS before addition of 0.2ml of crystal violet solution to each 
well and incubation for 10min. The excess crystal violet solution was washed 
away using distilled water where non-viable cells gets detached and washed 
off in the process, leaving the attached viable cells that retained the crystal 
violet stain. Remaining crystals were dissolved in a 1% SDS in 1X PBS 
solution and viability was determined by reading absorbance at wavelength 
595nm using a TECAN spectrophotometer.  
 
For survival assay in NPC primary cells, NPC patient’s biopsy was obtained 
under the consent of the patient. Single cell suspension was then extracted 
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from the biospsy. 5000 cells/well were seeded into a 96-well tissue culture 
plate. They were then treated with varying doses of TRAIL for a period of 
48hr. Cytotoxicity was determined by the MTT assay. After drug exposure, 
MTT solution was added to each well and incubation for 2hr. The plate was 
then spun at 4 000rpm for 20mins and the solution aspirated. Crystals were 
dissolved in DMSO and viability was determined by reading absorbance at 
wavelength 570nm using a TECAN spectrophotometer. 
 
(Crystal Violet Solution: 0.75% crystal violet in 50% ethanol:distilled water 
with 1.75% formaldehyde and 0.25% NaCl and stored at room temperature. 
MTT Solution: 3-5mg/ml MTT in PBS) 
 
Colony forming assay 
HK-1 (0.1x10
6
 cells/well) and C666-1 (0.2x10
6
 cells/well) cells were plated in 
a 24-well tissue culture plate (2 days prior treatment) and treated with 25ng/ml 
to 100ng/ml of TRAIL for 8hr. As this treatment period did not induce any 
visible cell death, cells were then washed and 10 000 cells from each treatment 
were re-plated into 100mm culture dishes and left to form colonies over a 
period of 10 to 14 days. Cell colonies were then stained with crystal violet. 
 
Propidium iodide staining - DNA fragmentation analysis 
Following treatment, the cells were washed and resuspended in 1ml of 1X 
PBS and immediately fixed with 70% ethanol:water while vortexing the cells. 
This is to prevent the cells from clumping together. The cells were then 
incubated for 30min at 4°C before they were washed twice with 1X PBS and 
resuspended in 500µl PI:RNase A solution for 2hr at 37
0
C for DNA content 
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analysis. At least 10 000 events were analysed by flow cytometry (Beckman 
Coulter, USA) with the excitation set at 488 nm and emission at 610 nm, after 
which they were analysed with the WinMDI software. Histogram data 
indicating percentage of cells with sub-diploid DNA are representative of 
three independent observations. In a typical DNA analysis, the apoptotic 
population of cells are reflected in the histograms as displaying hypodiploid 
DNA content. 
 
(Buffers: PI stock solution (50X) was dissolved in 38mM sodium citrate 
buffer to a stock concentration of 0.5mg/ml and kept in 4°C and protected 
against light exposure. RNase A was dissolved in 10mM Tris-HCl (pH 7.5) 
and 15mM NaCl to a stock concentration of 10mg/ml and kept at -20°C. 
PI:RNase A solution was freshly prepared with 1/50 volume of PI and 1/40 
volume of RNase A stock solution in 38mM sodium citrate buffer). 
 
Caspase activity assay 
Caspases -8, -9 and -3 activities were assayed using AFC-conjugated 





cells/well respectively for a 6-well tissue culture plate 2 days before treatment) 
were treated with TRAIL 25ng/ml and 100ng/ml respectively for 2hr, 4hr, 8hr, 
16hr and 24hr. Cells were then harvested and washed with 1X PBS, 
resuspended in chilled cell lysis buffer (BD Pharmingen, San Diego, CA, 
USA), and incubated on ice for 30 min before incubation with their respective 
substrates and real-time measurements of enzyme-catalysed release of AFC 
were obtained using TECAN spectrophotometer reader operating with 
Magellan software. Final fluorescence values obtained after 1hr incubation at 
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37ºC were normalized against the protein concentration of samples and plotted 
as x-fold increase in caspase activity over the untreated control.  
 
Western blot analysis 
Whole cell protein extracts were isolated after drug treatments using 1X RIPA 
lysis buffer. Sucrose density gradient fractions, cytosolic, mitochondria and 
plasma membrane fractions filtration were obtained using standard procedures 
(see each related method). Protein concentration was quantified using the 
Coomassie blue reagent. Briefly, 1µl of the supernatant was added to 200µl of 
Coomassie blue reagent into a 96-well plate and read for absorbance at 595nm 
using TECAN spectrophotometer. Equal amounts of proteins from the lysates 
were mixed with 5X Laemelli loading dye and boiled for 5min. The samples 
were then subjected to different concentrations (8%, 10% or 12%) of sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) depending 
on the molecular weight of the target proteins and transferred onto PVDF 
membranes (BioRad Laboratories) subsequently. The membrane was blocked 
with 5% (w/v) fat-free milk in TRIS buffered saline (TBS) containing 0.1% 
(v/v) Tween 20 (TBST) for 1hr and washed thrice with TBST to remove 
excess milk. The membrane was probed for the target protein with the relevant 
primary antibodies (refer to antibodies list above) overnight at 4ºC. The 
membrane was washed thrice to remove unbound primary antibody and 
probed again using appropriate HRP-conjugated secondary antibody in TBST 
containing 1% (w/v) fat-free milk at room temperature for 1hr. After three 
washes with TBST to remove any excess unbound secondary antibody, the 
proteins of interest were detected with Kodak Biomax MR X-ray film 
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(Eastman Kodak Co., Rochestor NY) by enhanced chemiluminescence using 
the SuperSignal Chemiluminescent Substrate (Pierce, Rockford, IL, USA). 
 
Buffers used in western blot analysis 
RIPA lysis buffer: 
50mM Tris-HCl pH 7.5, 150mM NaCl, 1% v/v TritonX-100, 1% v/v 
deoxycholic acid,  0.1%  v/v SDS, 1mM EDTA. Before use, the buffer was 
supplemented with protease inhibitors (1mM PMSF, 10μg/ml Aprotinine, 
20μg/ml Pepstatin A) and phosphatase inhibitors (1mM NaF, 1mM Na3VO4). 
 
Running Buffer for SDS-Page gel: 10X (2L) 
Tris-base 60g, glycine 288g, SDS 20g, top to 2L with dH2O. 
 
Transfer Buffer for western blot: 1X (5L) 
Tris-base 12.1g, glycine 57.84g, methanol 1L, top to 5L with dH2O. 
 
Lammeli Loading Buffer: 5X (10 ml) 
100mM Tris-HCL pH 6.8, 3.1ml (1M), SDS 1g (10%), glycerol 2ml (20%), β-
Mercaptoethanol 2.5ml (25%), Bromophenol blue 0.01g  (0.1%), top to 10 ml 
with 2.4ml distilled H2O. 
 
TBS: 
500ml 1M Tris-HCl (pH 7.4) with 87.6g of NaCl in 10L of distilled water and 
stored at room temperature. 
 
TBST: 




Isolation of cytosolic, mitochondria and plasma membrane fractions 
For isolation of the various cellular fractions, cells were harvested and washed 
once with ice-cold 1X PBS before incubation on ice for 10min in the 
extraction buffer. After incubation, the cells were homogenised with a dounce 
homogeniser and passaged for 10 strokes for HK-1 cells and 20 strokes for 
C666-1 cells before being centrifuged at 1000g for 10min at 4
0
C to remove 
debris. Following which, the supernatant was centrifuged again at 10 000g for 
20min at 4
0
C. The pellet obtained will be the mitochondria fraction and the 
mitochondria protein extracts were isolated using 1X RIPA lysis buffer. The 
supernatants were then subjected to a round of ultracentrifugation at 100 000g 
for 1hr at 4
0
C. The pellet obtained from the ultracentrifugation will be the 
plasma membrane fraction and the protein extracts were isolated using 1X 
RIPA lysis buffer. The supernatants will be the cytosolic fractions. All the 
fractions obtained were then subjected to SDS-PAGE and western blotting as 
stated above. 
 
(Extraction buffer: 50mM PIPES-KOH pH 7.4, 200mM mannitol, 68mM 
sucrose, 50mM KCl, 5mM EGTA, 2mM MgCl2, 1mM DTT, pH 7.4 
containing the protease inhibitor; 0.5 mM of PMSF). 
 
Isolation of membrane lipid rafts – sucrose gradient ultracentrifugation 




 cells respectively) were seeded 
in 100mm petri dishes 2 days before experiment. Cells were harvested and 
washed with ice-cold 1X PBS before incubating in 500ml of HEPES buffer 
containing 1% TritonX-100 for 10min. Lysates were then subjected to 1 round 
of freeze thaw action before homogenising it for 20 strokes with a dounce 
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homogeniser. The homogenised lysates were centrifuged at 400g for 10min at 
4
0
C to remove debris. Following which, the supernatant were subjected to 10 
passes through a 27G syringe. This is followed by sonication (3 sets of 10sec 
pulses at 40V) and protein quantification to determine equal amounts of 
protein used for subsequent ultracentrifugation. The lysate is mixed with an 
equal volume of 80% sucrose (w/v) in HEPES buffer, transferred to a 
centrifuge tube and overlaid with 2ml of 30% sucrose and 2ml of 5% sucrose 
solutions. The sucrose gradient was centrifuged for 21hr at 4ºC in a Beckman 
rotor at 32 000rpm and nine 0.5ml fractions were harvested separately. 40µl 
was taken from the fractions and subjected to SDS-PAGE and western blotting 
for relevant lipid raft marker and protein of interest. 
 
(HEPES Buffer: 25mM HEPES, 150mM NaCl, pH7.4 containing 1mM 
PMSF, 10mg/ml aprotinin, 20mg/ml pepstatin A and 10mg/ml leupeptin ) 
 
Analysis of cell surface levels of DR4 and DR5 





respectively for a 12-well tissue culture plate 2 days before experiment) were 
harvested and washed three times in 1X PBS supplemented with 0.5% BSA. 
Cells were then incubated with phycoerythrin (PE)-conjugated mouse 
monoclonal anti-human DR5 or DR4 for 45min at 4ºC as per manufacturer’s 
instructions before washing and resuspension in 1X PBS for flow analysis 
using an excitation wavelength of 488nm.  PE-conjugated mouse IgG2B was 
used as an isotype control. Data was analysed and histograms were plotted 




Confocal analysis of caspase-3 and TMTC2 




 respectively) were plated in a 12-
well plate on polylysine-coated coverslips. Cells were washed twice with 1X 
PBS and fixed with 2% paraformaldehyde in 1X PBS for 15min at room 
temperature. After which, cells were washed three times with 1X PBS and 
subjected to permeabilisation with 0.1% TritonX-100 in 1X PBS for 10min at 
room temperature.  Cells were then washed three times with 1X PBS followed 
by an hour blocking with 5% BSA in 1X PBS. Subsequently, cells were 
incubated with either mouse anti-caspase-3 or mouse anti-DDK (detection of 
overexpressed TMTC2) and rabbit anti-caveolin in 1X PBS with 5% BSA 
(1:200 dilution for anti-caspase-3 and anti-DDK; 1:400 dilution for anti-
caveolin) for 2hr. After that, they were washed three times with 1X PBS in 5% 
BSA followed by 1hr incubation with 1:300 dilution for Alexafluor-488  anti-
mouse secondary antibody (Invitrogen) and 1:400 dilution for Alexafluor-568 
anti-rabbit secondary antibody (Invitrogen) in 1X PBS with 5% BSA. Cells 
were similarly washed three times with 1X PBS before the coverslips were 
mounted on glass slides and imaged with Olympus Fluoview FV1000 confocal 
microscope and images analysed using Olympus Fluoview 1.7 viewer. 
 
Co-immunoprecipitation (Co-IP) assay 
Cells were harvested and washed once with ice cold 1X PBS and incubated for 
30 min with constant agitation at 4ºC in Co-IP buffer. The lysates were then 
centrifuged in a microcentrifuge at 12 000rpm for 10min at 4ºC. The 
supernatant were collected and pre-cleared with protein A agarose beads on a 
rotator for 4hr at 4ºC. After which, it was subjected to centrifugation at 12 
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000rpm for 10min at 4ºC. The supernatant (cell lysate) were collected for Co-
IP. 1mg of the cell lysate was incubated with 4ug of either mouse monoclonal 
anti-caspase-3 antibody or control mouse IgG for overnight on a rotator at 4ºC. 
On the next day, protein A agarose beads were added to each of the samples 
and rotated for another 2hr at 4ºC The complexes were then washed four times 
with the Co-IP buffer, centrifuged at 12 000rpm for 5min at 4ºC before boiling 
for 30min in 1X Lammelli loading buffer and used for SDS-PAGE and 
western blotting for the various protein. 
 
(Co-IP buffer: 50mM Tris-HCl, 150mM NaCl, pH7.4 containing 0.5% NP-40, 
1mM PMSF, 10mg/ml aprotinin, 20mg/ml pepstatin A, 10mg/ml leupeptin ) 
 
CM-H2DCFDA (5- (and-6)- chloromethyl- 2',7'- 
dichlorodihydrofluorescein diacetate, acetyl ester) staining – Detection of 
reactive nitrogen species 
HK-1 cells were seeded at 0.2x10
6 
cells/well in a 12-well tissue culture plate 2 
days before experiment. Cells were treated with TRAIL 25ng/ml for 2hr, 4hr, 
6hr and 8hr. Cells were then harvested and washed once with 1X PBS. 
Subsequently, cells were resuspended in 1X PBS containing 10uM CM-
H2DCFDA and incubated at 37ºC in the dark for 20min to ‘load’ the dye. 
After which, cells were pelleted at 1500rpm for 5min and resuspended in 1X 
PBS. At least 10 000 events were analysed by flow cytometry with the 
excitation set at 488nm and emission at 525nm, after which they were 
analysed with the WinMDI software. Final fluorescence values obtained were 
normalized against the untreated control and plotted as x-fold increase in 





TRAIL a potential therapeutics in NPC cell line HK-1 and C666-1 
TRAIL being able to induce apoptosis specifically to tumour cells is a 
potential alternative therapy for NPC. To date, 5 receptors had been identified 
to bind to TRAIL, however, only DR4 and DR5 contains the essential 
cytoplasmic death domains for the forward transmission of the apoptotic 
signal upon receptor ligation. 
 
To assess the possibility of TRAIL as a therapeutic for NPC, the expression of 
the functional TRAIL receptors, DR4 and DR5 has been analysed. The total 
protein level of DR4 and DR5 were first assessed by western blotting. Both 
receptors were found to be expressed in the NPC cell line (Fig 6A).  
 
In order for the receptors to receive signals from TRAIL, it has to be express 
on the surface of the cells. To that end, surface expression levels of TRAIL 
receptors, DR4 and DR5, were analysed. HK-1 and C666-1 cells in culture 
were stained with the anti-DR4 or anti-DR5 PE-conjugated antibody for flow 
cytometry analysis. DR4 and DR5 were both stained positive in the HK-1 and 
C666-1 cells (Fig 6B). This suggested the possibility of TRAIL as a NPC 


























Figure 6: Expression of death receptors 4 and 5 in NPC cell lines HK-1 and C666-1 
A. Expression level of DR4 and DR5 in HK-1 and C666-1 was screened  by SDS-PAGE and 
Western blot using total protein extract. B. Surface expression of DR4 and DR5 in HK-1 and 
C666-1 was analysed using flow cytometry. Cells were stained with phycoerythrin (PE)-

























TRAIL induces cell death in NPC cell line HK-1 and C666-1 
A dose response curve for TRAIL was established in HK-1 and C666-1 cells 
by evaluating the effect of increasing doses of TRAIL (0-100ng/ml) on cell 
viability for 24hr using the crystal violet assay (Fig 7A). HK-1 cells responded 
to TRAIL exposure in a dose dependent manner, with a LD50 of 
approximately 25ng/ml. In C666-1 cells, there was a relatively modest effect 
of TRAIL on cell viability as compared to HK-1 cells. Over a 24-hour 
treatment with TRAIL, a decreased in cell viability of HK-1 and C666-1 by 
about 60% and 25% respectively at 25ng/ml dose was observed. 
 
To evaluate that the drop in cell viability was a result of apoptosis, apoptotic 
characteristics of DNA fragmentation was analysed (Fig 7B). HK-1 and C666-
1 cells subjected to increasing doses (0-100ng/ml) of TRAIL for 24hr were 
fixed and stained with PI to assess for the extent of DNA fragmentation as a 
function of apoptosis after TRAIL treatment. Cells with fragmented DNA will 
appear as the sub-diploid (sub-G1) fraction of the cell cycle profile. A similar 
observation to that of the cell viability was observed. TRAIL was able to 
induce apoptosis in a dose dependent manner, with a LD50 of approximately 
25ng/ml in HK-1 cells. TRAIL effect in C666-1 was relatively modest as 
compared to HK-1 cells.   
 
For subsequent experiments, the chosen doses of TRAIL for HK-1 and C666-1 
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Figure 7: TRAIL-induced cell death in NPC cell lines HK-1 and C666-1 
A. HK-1 and C666-1 were treated with different doses of TRAIL (0-100µg/ml) for 24hr. 
Percentage of cell survival was determined by crystal violet assay. Data are expressed as 
means ± S.D of at least 3 independent experiments. B. HK-1 and C666-1 cells were treated 
with different doses of TRAIL (0-100µg/ml) for 24hr. PI staining was performed for cell cycle 
analysis. Histogram shown are representative of at least 3 independent experiments. 
 
 
Pre-incubation with either DR4 or DR5 blocking antibodies partially 
rescues HK-1 and C666-1 cells from TRAIL-induced cell death 
In order to verify that TRAIL is indeed causing apoptosis in the NPC cell 
lines, a reverse experiment of blocking TRAIL signal at the receptor level was 
carried out. 
 
Monoclonal antibodies that are able to bind DR4 or DR5 specifically were 
used to inhibit TRAIL-induced apoptosis.  They function as competitive 
inhibitors for binding to the death receptors. Hence, these blocking antibodies 
were added to cells in culture medium for 6hr, prior TRAIL treatment for 24hr 
before measuring cell viability using crystal violet assay (Fig 8). Blocking of 
either death receptors in HK-1 and C666-1 is only able to induce a partial 
rescue of the cells from TRAIL-induced cell death. A more complete rescue of 
cell death in HK-1 and C666-1 cells was observed in the double blocking of 

























Figure 8: Rescue of HK-1 and C666-1 cells from TRAIL-induced cell death with 
receptors blocking antibodies 
HK-1 and C666-1 cells were pre-incubated with receptor blocking antibodies for 6hr before an 
24hr treatment with TRAIL 25ng/ml and 100ng/ml respectively. Cell viability was determined 
using crystal violet assay. Upper panel: HK-1. Lower panel: C666-1. Data are expressed as 






































































Knock-down of either DR4 or DR5 confers moderate protection against 
TRAIL-induced apoptosis in HK-1 and C666-1 cells 
To further augment the observation made from the blocking antibodies 
experiment, we went on to do the knock-down experiments of death receptors. 
 
RNAi-mediated interference of DR4 or DR5 was carried out using 
Dharmafect-1 transfection reagent. HK-1 and C666-1 cells were then 
subjected to TRAIL treatment for 24hr before they were harvested to 
determine cell viability using crystal violet assay. Separate whole cell lysates 
were collected for western blotting to examine for successful knock-down of 
total protein levels of DR4 and DR5. β-actin was used as loading control.  
 
Results display a similar trend as that obtained from the experiment using 
receptor blocking antibodies. Knock-down of either death receptor 4 (Fig 9A) 
or death receptor 5 (Fig 9B) in HK-1 and C666-1 is only able to induce a 
partial rescue of the cells from TRAIL-induced cell death. Knocking down of 
DR4 alone exhibits a substantial rescue of HK-1 and C666-1 cells from 
TRAIL-induced cell death as compared to that of DR5 knock-down. This 



















































































































Figure 9: Knock-down of either DR4 or DR5 confers partial protection against TRAIL-
induced apoptosis in HK-1 and C666-1 cells 
A. HK-1 and C666-1 cells were transiently transfected with either scrambled siRNA or siRNA 
against DR4 and allowed to recover for 48hr post transfection. HK-1 and C666-1 cells were 
subjected to TRAIL treatment at 25ng/ml and 100ng/ml respectively for 24hr and cell viability 
were determined using crystal violet assay. Upper panel: HK-1. Lower panel: C666-1. Data 
are expressed as means ± S.D of at least three independent experiments. B. HK-1 and C666-1 
cells were transiently transfected with either scrambled siRNA or siRNA against DR5 and 
allowed to recover for 24hr post transfection. HK-1 and C666-1 cells were subjected to 
TRAIL treatment at 25ng/ml and 100ng/ml respectively for 24hr and cell viability were 
determined using crystal violet assay. Upper panel: HK-1. Lower panel: C666-1. Data are 
































































TRAIL treatment reduces the tumour colony forming ability of HK-1 and 
C666-1 cells 
Given the ability of TRAIL to induce cell death upon short-term treatment, it 
would be of interest to look at the effect of TRAIL in the long-term 
survival/proliferative capacity of tumour cells as well. This was done by 
evaluating the effect of the TRAIL treatment on HK-1 and C666-1 cells 
colony forming ability. 
 
HK-1 and C666-1 cells were exposed to increasing doses of TRAIL (0-
100ng/ml) for 8hr. An equal number of cells were then seeded onto 100mm 
petri dishes and allowed to form colonies over a period of 10 to 14 days. Upon 
staining by crystal violet stain, a marked reduction in colony formation for 
cells treated with TRAIL was observed and such an effect was more 

























Figure 10: Reduction in tumour colony forming abilities of HK-1 and C666-1 cells on 
TRAIL treatment  
HK-1 and C666-1 cells were treated with different doses of TRAIL (0-100µg/ml) for 8hr. The 
cells were then re-seeded onto 100mm petri dishes and allowed to form colonies over 10 to 14 




























TRAIL treatment induces, and is dependent on, caspase activation  
Death receptor mediated apoptosis requires the activation of the caspase 
cascade, which is responsible for the cleavage of cellular substrates to bring 
about the controlled demise of cells. In order to find out whether caspase were 
involved in TRAIL-induced cell death in the NPC cell line HK-1 and C666-1, 
caspase processing and activity were being evaluated.  
 
HK-1 and C666-1 cells treated with TRAIL for different time (2hr, 4hr, 8hr, 
16hr and 24hr) shows a strong amplifications of caspase-8, caspase-9 and 
caspase-3 activities beginning from 2hr and peaking at around 8hr (Fig 11A).  
 
Detection of caspase activities through the use of fluorogenic substrates is 
convenient, rapid and ideal for high-throughput, quantitative analysis. 
However, it may not be very specific because different caspases preferentially 
but not exclusively recognise and cleave after a different tetrapeptide 
sequence. Consequently, results obtained from fluorogenic substrates assays 
must be ideally verified through western blot using specific anti-caspase 
antibodies. Upon treatment with TRAIL for 6hr, processing of initiator 
procaspases-8 and -9 as well as executioner procaspases-3 were observed in 
HK-1 and C666-1 cells (Fig 11B). This was indicated by the appearance of 

















































































































Figure 11: TRAIL treatment in HK-1 and C666-1 cells mediates processing and 
activation of procaspases 
A. HK-1 and C666-1 treated with TRAIL 25ng/ml and 100ng/ml respectively for 2hr, 4hr, 
8hr, 16hr and 24hr. Whole cell lysates were used to determine the activities of caspase-8, 
caspase-9 and caspase-3 using fluorescent-conjugated substrates. Data are expressed as means 
± S.D of at least three independent experiments. B. HK-1 and C666-1 were treated with 
TRAIL 25ng/ml and 100ng/ml respectively for 6hr. Whole cell lysates were then used to assay 

















In order to validate the involvement of caspase-mediated cell death in the NPC 
system, the effect of the pan-caspase inhibitor ZVAD-fmk was investigated. 
Prior addition of ZVAD-fmk restored cell viability of TRAIL-treated HK-1 
(Fig 12A) and C666-1 (Fig 12B) cells, back to almost 100%, after 24hr of 
treatment. In addition, the processing and activation of caspases-8, -9 and -3 
resulting from the treatment of TRAIL were blocked by ZVAD-fmk at 3hr and 
6hr in both HK-1 (Fig 13A and B) and C666-1 cells (Fig 13C and D).  
 
Taken together, these results show that TRAIL induces a caspase-dependent 






























        
 
Figure 12: TRAIL mediated apoptosis in HK-1 and C666-1 cells in a caspase-dependent 
manner 
A. HK-1 was incubated with pan-caspase inhibitor, ZVAD-fmk (25µM and 50µM) for 1hr 
followed by 24hr treatment with TRAIL 25ng/ml. Cell viability was assessed by crystal violet 
staining. Right panel: Crystal violet staining of viable cells after drugs treatment. Left panel: 
Percentage of cell survival determined by crystal violet assay. Data are expressed as means ± 
S.D of at least 3 independent experiments. B. C666-1 was incubated with pan-caspase 
inhibitor, ZVAD-fmk (25µM and 50µM) for 1hr followed by 24hr treatment with TRAIL 
100ng/ml. Cell viability was assessed by crystal violet staining. Right panel: Crystal violet 
staining of viable cells after drugs treatment. Left panel: Percentage of cell survival 
determined by crystal violet assay. Data are expressed as means ± S.D of at least 3 
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Figure 13: Inhibition of TRAIL-induced processing and activation of procaspases in HK-
1 and C666-1 cells by pan-caspase inhibitor, ZVAD-fmk  
HK-1 was incubated with pan-caspase inhibitor, ZVAD-fmk (25µM) for 1hr followed by 3hr 
(T3H) and 6hr (T6H) treatment with TRAIL 25ng/ml. A. Whole cell lysates were used to 
determine the activities of caspase-8, caspase-9 and caspase-3 using fluorescent-conjugated 
substrates. Data are expressed as means ± S.D of at least three independent experiments. B. 
Whole cell lysates were then used to assay for caspase-8, caspase-9 and caspase-3 processing 
by SDS-PAGE and western blotting.  
C666-1 was incubated with pan-caspase inhibitor, ZVAD-fmk (25µM) for 1hr followed by 
3hr (T3H) and 6hr (T6H) treatment with TRAIL 100ng/ml. C. Whole cell lysates were used to 
determine the activities of caspase-8, caspase-9 and caspase-3 using fluorescent-conjugated 
substrates. Data are expressed as means ± S.D of at least three independent experiments. D. 
Whole cell lysates were then used to assay for caspase-8, caspase-9 and caspase-3 processing 






















TRAIL induces mitochondrial membrane potential depolarization(ΔΨm ) 
Caspase-9, which is a typical caspase for the intrinsic mitochondria death 
pathway, had been activated in HK-1 and C666-1. This suggests the 
involvement of the mitochondria pathway in the TRAIL-induced apoptosis in 
the NPC cell lines.  
 
MOMP is one of the initial triggers for the intrinsic pathway of apoptosis. It 
has been shown that MOMP involves a drop in the mitochondrial 
transmembrane potential (ΔΨm), therefore, we set out to investigate the effect 
of TRAIL on ΔΨm. 
 
HK-1 and C666-1 cells were treated with TRAIL for 2hr followed by ΔΨm 
analysis with DiOC6 by flow cytometry. The uncoupler CiCCP was used as a 
positive control for membrane depolarisation. Result shows that TRAIL was 
able to induce a drop of the mitochondrial transmembrane potential in the 









Figure 14: TRAIL induces a drop in mitochondrial transmembrane potential in HK-1 
and C666-1 cells 
HK-1 and C666-1 cells were treated with TRAIL 12.5ng/ml, 25ng/ml and 50ng/ml, 100ng/ml 
respectively for 2hr. Cells were stained with DiOC6 and analysed by flow cytometry and 
histograms plotted. Data shown are representative of at least 3 independent experiments.  
HK-1  C666-1 
-- Co 
-- CiCCP (positive co) 
-- TRAIL 12.5ng/ml 
-- TRAIL 25ng/ml 
-- Co 
-- CiCCP (positive co) 
-- TRAIL 50ng/ml 
-- TRAIL 100ng/ml 
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TRAIL engages the mitochondrial apoptotic pathway 
Following MOMP, the release of apoptogenic factors like cytochrome c from 
the mitochondria marks an important step in the intrinsic apoptotic pathway as 
it engages the apoptotic cascade. 
 
Earlier results showed that TRAIL is able to induce MOMP, hence 
investigation on the subsequent mitochondrial events such as the release of 
apoptogenic factors were carried out. 
 
HK-1 and C666-1 cells were treated with TRAIL for 16hr. Mitochondria- and 
cytosol- enriched fractions of the TRAIL-treated cells were obtained and 
analysed via western blotting for the aforementioned proteins. Result shows 
that on TRAIL treatment in HK-1 and C666-1 cells, there is a drop in 
mitochondria cytochrome c with a corresponding increase in cytosolic 
cytochrome c (Fig 15A), suggesting the release of pro-apoptotic mitochondria 
cytochrome c into the cytosol.  
 
In literature, TRAIL has been shown to trigger the death receptor pathway and 
for TRAIL to engage the intrinsic death pathway it requires the employment of 
an activated truncated cross-talk mediator, tBid. Thus the present of the 
truncated bid was also being assessed. From the result, it was observed that 
upon TRAIL treatment, Bid in HK-1 and C666-1 is being cleaved (Fig 15B). 
This indicates the present of an active cross-talk mediator tBid and that 




















Figure 15: TRAIL induces processing of pro-Bid and release of cytochrome c into the 
cytosol in HK-1 and C666-1 cells 
A. HK-1 and C666-1 cells were treated with 25ng/ml and 100ng/ml respectively for 16hr. 
Levels of cytochrome c in the mitochondrial and cytosolic fractions were then assayed by 
SDS-PAGE and western blotting. B. HK-1 and C666-1 cells were treated with 25ng/ml and 
100ng/ml respectively for 6hr. Whole cells lysates were collected and assessed for cleavage of 
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Overexpression of Bcl-2 confers protection against TRAIL-induced 
apoptosis 
Bcl-2 protein is an important guardian of the mitochondrial events by 
regulating the release of apoptotic proteins from the mitochondria. To further 
validate the involvement of mitochondria in the TRAIL-induced cell death, we 
next overexpressed Bcl-2 in HK-1 and C666-1 cells prior to TRAIL treatment. 
It is noteworthy that overexpression of Bcl-2 protects HK-1 (Fig 16A) and 
C666-1 (Fig 16B) cells against TRAIL-induced cell death. This demonstrates 
that TRAIL-induced apoptosis in these cells was mitochondrial-dependent, 
which is typical of a type II mitochondrial-dependent cell.  
 
These data highlighted the involvement of the mitochondria in TRAIL-




































Figure 16: Overexpression of Bcl-2 confers protection against TRAIL-induced apoptosis 
in HK-1 and C666-1 cells 
A. HK-1 was transiently transfected with 2µg of Bcl-2 plasmid for 24hr. Cells were then 
treated with TRAIL 25ng/ml for 24hr. Upper panel: Western blot showing overexpression of 
Bcl-2 proteins in HK-1. Lower panel: Percentage of cell survival was determined by the 
crystal violet assay. Data are expressed as means ± S.D of at least three independent 
experiments.  B. C666-1 was transiently transfected with 2µg of Bcl-2 plasmid for 24hr. Cells 
were then treated with TRAIL 100ng/ml for 24hr. Upper panel: Western blot showing 
overexpression of Bcl-2 proteins in C666-1. Lower panel: Percentage of cell survival was 
determined by the crystal violet assay. Data are expressed as means ± S.D of at least three 
























































TRAIL induces cell death as efficiently if not better than conventional 
NPC therapeutics 
With the knowledge that TRAIL is able to induced killing in NPC cell lines, 
the ultimate aim is still to look at the efficacy of TRAIL in comparison to the 
conventional therapy of 5-Flurouracil and Cisplatin.  
 
The killing capacity of TRAIL, 5-Flurouracil and Cisplatin was established in 
HK-1 and C666-1 cells by evaluating the effect of increasing doses of TRAIL 
(0-100ng/ml), 5-Flurouracil (0-400µM) and Cisplatin (0-80µM) on cell 
viability for 24hr using the crystal violet assay (Fig 17). In HK-1, TRAIL was 
able to reduce cell viability more efficiently than the 2 conventional drugs. As 
for C666-1, TRAIL is working as effectively as the 2 conventional drugs if not 
better. 
 















Figure 17: Comparison of TRAIL-induced apoptosis in HK-1 and C666-1 to the 
conventional NPC therapeutics 
HK-1 and C666-1 were treated with different doses of TRAIL (0-100µg/ml), 5-Fluorouracil 
(0-400µM) and Cisplatin (0-80µM) for 24hr. Cell viability was measured by crystal violet 




































TRAIL induces cell death in NPC primary cells 
To further augment the possibility of TRAIL as a NPC therapeutic, NPC 
primary cells were obtained. They were subjected to increasing doses of 
TRAIL (0-400ng/ml) for 48hr. The effects of TRAIL on cell viability of the 
biopsy were assessed by MTT assay. The screen done on NPC primary cells 
showed that TRAIL is able to induce more than 20% cell death at dose of 
100ng/ml in three of the four NPC primary cells sample tested (Fig 18).  
 
On the whole, with the efficacy of TRAIL compared to the conventional drug 
in the NPC cell lines and NPC primary cells, TRAIL is a strong candidate as 
an alternative NPC therapy.  
 
However, an interesting observation was made during the analysis. An 
atypical early activation of effector caspase-3 was observed. Therefore in the 
next segment, a series of studies were undertaken to further investigate for 














Figure 18: Induction of apoptosis in NPC primary cells 
NPC patient 6, 16, 18 and 24 biopsies were treated with different doses of TRAIL (0-
400µg/ml) for 48hr. Cell viability was measured by MTT assay. Expression levels of DR4 and 





Knock-down of caspase-8 and not caspase-3 confers protection against 
TRAIL-induced apoptosis in the NPC cell lines 
In a typical death receptor mediated apoptosis, TRAIL binds to its cell surface 
death receptors, inducing their trimerisation.  Following which, adaptor 
proteins FADD are then recruited. This in turn mediates the recruitment of 
initiator procaspase-8 via its DED to form the DISC. At the DISC, procaspase-
8 molecules are activated by autoproteolysis. The activated initiator caspases 
then activate effector procaspases such as caspase-3 and -6 to effect apoptosis. 
However an atypical early activation of effector caspase-3 was observed (Fig 
11A). The activity of caspase-3 was detected at 2hr, the same time as the 
initiator caspases. Thus, could it be possible that caspase-3 is upstream of 
caspase-8?  
 
To answer the question, silencing of caspase-8 and -3 were carried out.  This 
would decipher the sequence of activation of caspase-8 and -3 in the TRAIL-
induced cell death in HK-1 and C666-1 cells.   
 
RNAi-mediated interference of either caspase-8 or caspase-3 was carried out 
using Dharmafect-1 transfection reagent and HK-1 and C666-1 cells were 
subjected to TRAIL treatment for 24hr before they were harvested to 
determine cell viability using crystal violet assay. Separate whole cell lysates 
were collected for western blotting to examine for successful knock-down of 




Result shows that only the knock-down of caspase-8 is able to rescue the HK-
1 (Fig 19A) and C666-1 (Fig 19B) cells from TRAIL-induced cell death. The 
rescue observed by the knock-down of caspase-3 is very minimal.  
 
To further validate the observation that the knock-down of caspase-8 is able to 
confer protection for HK-1 and C666-1 cells from TRAIL-induced apoptosis, 
activity and processing of caspase-8 and -3 were also assessed.  A drop in 
caspase-8 and -3 activity as well as their processing was observed in TRAIL-
treated HK-1 (Fig 20A and B) and C666-1 (Fig 20C and D) cells with the 
knock-down of caspase-8. The knocking down of caspase-3 has minimal 
effect on the activity and processing of caspase-8 and -3 in both HK-1 (Fig 
20A and B) and C666-1 (Fig 20C and D) cells. 
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Figure 19: Knock-down of caspase-8 and not caspase-3 confers protection against 
TRAIL- induced apoptosis in HK-1 and C666-1 cells 
A. HK-1 cells were transiently transfected with either scrambled siRNA or siRNA against 
caspase-8 or caspase-3 and allowed to recover for 24hr post transfection. HK-1 cells were 
subjected to TRAIL treatment at 25ng/ml for 24hr. Upper panel: Western blot showing 
knock-down of caspase-8 or caspase-3 proteins in HK-1. Middle panel: Crystal violet 
staining of viable cells after drugs treatment. Lower panel: Percentage of cell survival 
determined by crystal violet assay. Data are expressed as means ± S.D of at least 3 
independent experiments. B. C666-1 cells were transiently transfected with either scrambled 
siRNA or siRNA against caspase-8 or caspase-3 and allowed to recover for 24hr post 
transfection. C666-1 cells were subjected to TRAIL treatment at 100ng/ml for 24hr. Upper 
panel: Western blot showing knock-down of caspase-8 or caspase-3 proteins in C666-1. 
Middle panel: Crystal violet staining of viable cells after drugs treatment. Lower panel: 
Percentage of cell survival determined by crystal violet assay. Data are expressed as means ± 
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Figure 20: knock-down of caspase-8 and not caspase-3 inhibits TRAIL-induced 
processing and activation of procaspases-8 and -3 in HK-1 and C666-1 cells  
HK-1 cells were transiently transfected with either scrambled siRNA or siRNA against 
caspase-8 or caspase-3 and allowed to recover for 24hr post transfection. HK-1 cells were 
subjected to TRAIL treatment at 25ng/ml for 6hr. A. Whole cell lysates were used to 
determine the activities of caspase-8 and caspase-3 using fluorescent-conjugated substrates. 
Data are expressed as means ± S.D of at least three independent experiments. B. Whole cell 
lysates were then used to assay for caspase-8 and caspase-3 processing by SDS-PAGE and 
western blotting.  
C666-1 cells were transiently transfected with either scrambled siRNA or siRNA against 
caspase-8 or caspase-3 and allowed to recover for 24hr post transfection. C666-1 cells were 
subjected to TRAIL treatment at 100ng/ml for 6hr. C. Whole cell lysates were used to 
determine the activities of caspase-8 and caspase-3 using fluorescent-conjugated substrates. 
Data are expressed as means ± S.D of at least three independent experiments. D. Whole cell 
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Caspase-3 is found to be in the cell surface membrane of the NPC cell line 
With caspase-3 still downstream of the TRAIL signalling cascade, the next 
question to address would be why is there such early caspase-3 activation? 
 
A study by Salah et. al. showed that caspase-3 is found in the lipid rafts of 
untreated Jurkat cells and peripheral T-lymphocytes. They showed that 
caspase-3 is a component of the DISC, in close proximity to caspase-8. 
Inferring from this study, it suggests that caspase-3 of HK-1 and C666-1 might 
be in the lipid rafts, in close proximity to caspase-8, giving rise to the early 
activation of caspase-3 observed. 
 
To validate the hypothesis that caspase-3 is found in the cell surface 
membrane of HK-1 and C666- cells, distinct raft regions on cell surface 
membrane were isolated on a sucrose-density gradient. A typical feature of 
lipid rafts is their resistance to extraction by the non-ionic detergent Triton-X 
in a sucrose containing density gradient at 4ºC. Thus, whole cell lysates of 
untreated HK-1 and C666-1 cells were collected in Triton-X containing buffer 
at low temperature and subjected to ultracentrifugation for 21hr on a sucrose-
density gradient. After which, 9 equal volume fractions were collected. Each 
fraction was then evaluated by western blotting for the presence caspase-3 and 
raft marker, flotillin. As shown in Fig 21, majority of the raft marker appear in 
fractions 4-6 of the sucrose gradient after ultracentrifugation. Corresponding 
to the fractions of the raft marker, caspase-3 was also present. The more 
TRAIL sensitive HK-1 (Fig 21 upper panel) cells were observed to have more 
caspase-3 in the lipid raft fractions as compared to the less TRAIL sensitive 
101 
 
C666-1 (Fig 21 lower panel) cells. The presence of caspase-3 in the lipid raft 














Figure 21: Presence of caspase-3 in the lipid rafts enriched fractions of sucrose density 
gradients 
Untreated HK-1 and C666-1 cells were harvested for sucrose-gradient ultracentrifugation. 
Subsequently, 9 equal fractions were obtained and each fraction was used to analyse for 





















To further verify the hypothesis, visual analysis on the surface distribution of 
caspase-3 using confocal microscopy was carried out. HK-1 and C666-1 cells 
were first seeded on glass-bottom chambers followed by fixing and then 
permeabilising the cell membrane. They were stained for 2hr with primary 
antibodies against caspase-3 and caveolin-1, a specific raft marker. 
Subsequently, the cells were incubated with the respective fluorescence-
conjugated secondary antibodies for 2hr before analysis using confocal 
microscopy. Similar results to that of the lipid raft experiment were observed 
for confocal microscopy. Fig 22 reveals an overlapping staining pattern of 
both caveolin-1 (red fluorescence) and caspase-3 (green fluorescence) around 
the cells, suggesting co-localisation (yellow staining around the cells in the 
merge field) of caveolin-1 and caspase-3. In HK-1 (Fig 22 upper panel) cells, 
a more intense caspase-3 staining on the cell membrane was observed. In 
contrast, C666-1 (Fig 22 lower panel) cells exhibits a more diffused caspase-3 
staining on the cell membrane.   
 
In summary, caspase-3 was found to be in the cell surface membrane of HK-1 
and C666-1 cells. In addition, the more TRAIL sensitive HK-1 cells were 
observed to have more caspase-3 in the cell surface membrane as compared to 






















Figure 22: Localisation of caspase-3 in the membrane in HK-1 and C666-1 cells 
Untreated HK-1 and C666-1 cells were plated on glass-bottom chambers.  Confocal analysis 
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Caspase-3 contains no membrane targeting signal sequences 
In the classical apoptotic pathway, caspase-3 was known to be a cytosolic 
protein. However, based on the result described above, caspase-3 was found to 
be on the cell surface membrane. Often, membrane protein would contain 
membrane localising signal targeting them to the membrane. Thus the logical 
approach would be to check if the caspase-3 protein sequences contain any 
membrane targeting signal sequences. Using the iPSORT prediction software, 
no membrane localising signal was found on caspase-3 (Fig 23). Therefore, 
another series of experiments were carried out to decipher how caspase-3 




Figure 23: Absence of signal sequences in caspase-3 







Caspase-3 associates with a novel membrane protein, TMTC2, at the cell 
surface membrane 
With no membrane targeting signal, another possible way for caspase-3 to 
bind to the membrane would be to associate with other membrane protein. In 
order to find out the membrane protein that caspase-3 is associating with, co-
immunoprecipitation assay using anti-caspase-3 antibody was done on HK-1 
lipid rafts extract. The interacting partners were then resolved on a SDS-
PAGE and subjected to MALDI TOF-TOF analysis (service provided by 
Protein and Proteomics Centre in department of biological science, NUS). A 
potential candidate, transmembrane and tetratricopeptide repeat containing 2 
(TMTC2) protein was identified. TMTC2 is a multi-pass membrane protein 
containing 10 tetratricopeptide repeat (TPR). It mediates protein-protein 
interactions and the assembly of multi-protein complexes. It is encoded by the 
TMTC2 gene located in chromosome 12.  
 
With the possible target being identified, its expression in the HK-1 and C666-
1 cells was analysed. Western blot analysis of the total protein extract of HK-1 
and C666-1 cells reveals the present of TMTC2 protein in the 2 cell lines (Fig 
24).  In addition, a differential in TMTC2 expression was also observed in the 
2 cell line. The more TRAIL sensitive HK-1 cells were found to have a higher 
level of TMTC2 as compared to the less TRAIL sensitive C666-1 cells. 
 
With the abundance of TMTC2 in the HK-1 cells, the detection of TMTC2 
would be much easier in this cell line. Thus for the subsequent experiment, 










Figure 24: Expression of TMTC2 protein in HK-1 and C666-1 
Expression level of TMTC2 in HK-1 and C666-1 were screened by SDS-PAGE and western 
blot using total protein extract. 
 
 
TMTC2 is expressed in the HK-1 cells, its localisation within the cells is next 
being assessed. Cell membrane-, mitochondria- and cytosol- enriched fractions 
of the HK-1 cells were obtained and analysed via western blotting for 
TMTC2. From Fig 25, it was observed that TMTC2 is localised to the cell 
membrane-enriched fraction. This indicates that TMTC2 is at the cell surface 
membrane and is a possible protein target to which caspase-3 is associating 
with at the membrane. 
 
The hypothesis is that caspase-3 is associated with TMTC2 at the membrane. 
In order for this association to happen, the 2 protein has to be in the same 
compartment within the cells. Fig 26A shows that TMTC2 and caspase-3 are 
both present in the cell membrane-enriched fraction. A similar observation 
was also obtained from the lipid raft fraction (Fig 26B). Both proteins were 
identified in the lipid raft fraction. This further suggests the possibility of 
TMTC2 as a target to which caspase-3 is associating with at the membrane. 
 













Figure 25: Localisation of TMTC2 to the membrane fraction in HK-1 cells 
Untreated HK-1 cells were subjected to cell fractionation. Localisation of TMTC2 in the 
mitochondria, cytosolic and plasma membrane fractions were then assayed by SDS-PAGE 













Figure 26: Localisation of TMTC2 and caspase-3 to the membrane and lipid raft 
fraction in HK-1 cells 
A. Untreated HK-1 cells were subjected to cell fractionation. Localisation of TMTC2 and 
caspase-3 in the mitochondria, cytosolic and plasma membrane fractions were then assayed by 
SDS-PAGE and western blotting. B. Untreated HK-1 cells were subjected to sucrose-gradient 
ultracentrifugation and the lipid raft fraction isolated. Localisation of TMTC2 and caspase-3 
in the lipid raft were then assayed by SDS-PAGE and western blotting. 
 
 




















To verify that caspase-3 is associating with TMTC2, whole cell lysates and 
lipid raft extract of HK-1 cells were subjected to co-immunoprecipitation with 
anti-caspase-3 antibody and western blotting was performed to analyse for 
TMTC2. The result (Fig 27) shows that TMTC2 is being pulled down together 
with caspase-3. The pulling down of TMTC2 together with caspase-3 in the 
lipid raft extract suggests the association of caspase-3 to TMTC2 at the cell 








Figure 27: Association of caspase-3 with TMTC2 in HK-1 cells 
Total lysate and lipid raft of untreated HK-1 cells were subjected Co-immunoprecipitation 
assay with anti-caspase-3 antibody.  TMTC2 association with caspase-3 were then assayed by 



























Knock-down of TMTC2 decreases the amount of membrane-associated 
caspase-3 in HK-1 cells 
Results so far suggested that TMTC2 could be the target protein tethering 
caspase-3 to the cell surface membrane. If the observation was to hold true, 
the removal of TMTC2 would be able to block the caspase-3 from associating 
to the membrane. Therefore, silencing of TMTC2 was carried out and the 
localisation of caspase-3 to the cell surface membrane was analysed.  
 
RNAi-mediated interference of TMTC2 in HK-1 cells was carried out using 
Dharmafect-1 transfection reagent. Cell membrane- and cytosol- enriched 
fractions of the transfected HK-1 cells were then extracted for western blotting 
to examine for TMTC2 and caspase-3 localisation. Separate whole cell lysates 
were also collected to examine for the successful knock-down of total protein 
levels of TMTC2 using β-actin as loading control.  
 
Fig 28 (upper panel) shows the successful knock-down of TMTC2 in HK-1 
cells and the knock-down was also reflected in the cell membrane-enriched 
fraction of the TMTC2 siRNAs transfected HK-1 cells (Fig 28 lower panel). 
With the drop in the amount of membrane TMTC2, a corresponding decrease 
in the membrane-associated caspase-3 was also observed (Fig 28 lower panel). 
The knocking down of TMTC2 has no effect on the total protein expression of 
caspase-3 in HK-1 cells (Fig 28 upper panel).  Now, those caspase-3 which is 
not able to be associated to the membrane due to the drop in TMTC2 moves to 
and resides in the cytosol. This was reflected in the corresponding increase in 
the cytosolic caspase-3 in the TMTC2 siRNAs transfected HK-1 cells (Fig 28 

















Figure 28: Knock-down of TMTC2 decreases the amount of membrane-associated 
caspase-3 
HK-1 cells were transiently transfected with either scrambled siRNA or siRNA against 
TMTC2 and allowed to recover for 48hr post transfection. HK-1 cells were subjected to cell 
fractionation. Upper panel: Western blot showing the knock-down of TMTC2 protein. 
Lower panel: Levels of TMTC2 and caspase-3 in the plasma membrane and cytosolic 
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In addition, confocal analysis of the TMTC2 siRNAs transfected HK-1 cells 
was carried out. The cells were stained for caspase-3 and caveolin-1 to 
observe the effect of the knock-down of TMTC2 on the distribution of 
caspase-3. In TMTC2 siRNAs transfected HK-1 (Fig 29B lower panel) cells, a 
more diffuse caspase-3 (green fluorescence) staining on the cell membrane 
was observed as compared to the scrambled siRNAs transfected HK-1 (Fig 
29B upper panel) cells. The caveolin-1 and caspase-3 co-localising (yellow 
staining around the cells in the merge field) signal on the cell surface 
membrane was also more diffuse in the TMTC2 siRNAs transfected HK-1 
cells as compared to the scrambled siRNAs transfected HK-1 cells. 
 
On the whole, the experiments show that, a drop in membranes-associated 
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Figure 29: Knock-down of TMTC2 prevents association of caspase-3 to the cell 
membrane 
HK-1 cells were plated on glass-bottom chambers and transiently transfected with either 
scrambled siRNA or siRNA against TMTC2. The cells were allowed to recover for 48hr post 
transfection. A. Western blot showing the knock-down of TMTC2 protein. B. Upper panel: 
Confocal analysis for caspase-3 and caveolin-1 were carried out in cells transfected with 
scrambled siRNA. Lower panel: Confocal analysis for caspase-3 and caveolin-1 were carried 

























Overexpression of TMTC2 increases association of caspase-3 to the cell 
membrane in C666-1  
Next, further experiment was done on C666-1 cells, which exhibits a low 
background level of TMTC2 and little membrane-associated caspase-3, to 
verify that TMTC2 is the possible target protein tethering caspase-3 to the cell 
surface membrane.  
 
C666-1 was overexpressed with TMTC2 (Fig 30A) and confocal analysis was 
then carried out to observe the distribution of the overexpressed TMTC2. 
From Fig 30B, it was observed that the overexpressed TMTC2 is present on 
the cell surface membrane. This was indicated by the intense TMTC2 (green 
fluorescence) stain around the cell surface.  
 
Furthermore, confocal analysis of the TMTC2 transfected C666-1 cells stained 
for caspase-3 and caveolin-1 was carried out to observe the effect of the 
TMTC2 overexpression on the distribution of caspase-3. In TMTC2 
overexpressed C666-1 (Fig 30C lower panel) cells, a more focus caspase-3 
(green fluorescence) staining on the cell membrane was observed as compared 
to the vector transfected C666-1 (Fig 30C upper panel) cells. The caveolin-1 
and caspase-3 co-localising (yellow staining around the cells in the merge 
field) signal on the cell surface membrane was also more intense in the 
TMTC2 overexpressed C666-1 cells as compared to the vector transfected 
C666-1 cells. 
 
Collectively, it was demonstrated that caspase-3 is associating with TMTC2 at 

























Figure 30: Overexpression of TMTC2 increases association of caspase-3 to the cell 
membrane in C666-1 cells 
C666-1 cells were plated on glass-bottom chambers and transiently transfected with 4µg of 
TMTC2 plasmid for 48hr. A. Western blot showing the overexpression of TMTC2 protein. B. 
Confocal analysis for overexpressed TMTC2 and caveolin-1 were carried out in cells 
transfected with TMTC2. C. Confocal analysis for caspase-3 and caveolin-1 were carried out 




















TRAIL treatment increases total TMTC2 protein level in HK-1 cells 
TMTC2 is a very novel protein with nothing much known about it. The 
information from the experiment so far suggested that TMTC2 is involved in 
the TRAIL-induced cell death in the NPC model. Thus it would be of interest 
to see if TRAIL has any effect on TMTC2.  
 
Expression kinetics (0-24hr) for TMTC2 was established in HK-1 cells. The 
effect of 25ng/ml of TRAIL on the total protein expression level for TMTC2 
at the various hours was assessed using western blotting. Result (Fig 31) 
shows that there was no discernable change to the TMTC2 protein level till 
2hr exposure to TRAIL. A detectable increase in level of TMTC2 was 
detected after 4hr and the expression level was sustained to 8hr. After which, a 







Figure 31: TRAIL induces an increased in TMTC2 protein level in HK-1 cells 
HK-1 cells were treated with TRAIL 25ng/ml for 2hr, 4hr, 6hr, 8hr, 16hr and 24hr. Whole cell 
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TRAIL treatment increases membrane-associated TMTC2 in HK-1 cells 
TRAIL is able to increase the total TMTC2 level in HK-1 cells, thus the next 
step is to find out if there is a corresponding increase at the cell surface 
membrane. 
 
HK-1 cells were treated with 25ng/ml of TRAIL for 2hr and 6hr. Cell 
membrane- and cytosol- enriched fractions of the TRAIL-treated HK-1 cells 
were then extracted for western blotting to examine for TMTC2 localisation. 
On TRAIL treatment, the total TMTC2 protein level increases (Fig 32 upper 
panel). A corresponding increase in TMTC2 level was also observed in the 
cell membrane-enriched fraction of the treated HK-1 cells (Fig 32 lower 













Figure 32: TRAIL induces an increased in membrane-associated TMTC2 in HK-1 cells 
HK-1 cells were treated with TRAIL 25ng/ml for 2hr and 6hr and subjected to cell 
fractionation. Upper panel: Western blot showing the TMTC2 protein level with TRAIL 
treatment. Lower panel: Levels of TMTC2 in the plasma membrane and cytosolic fractions 
were then assayed by SDS-PAGE and western blotting. 
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As mention previously, caspase-3 is associated with TMTC2 at the cell surface 
membrane. So with the increase in membrane-associated TMTC2 upon 
TRAIL treatment, would there be a corresponding increase in membrane-
associated caspase-3? From Fig 33, there is an increase in both the caspase-3 
(green fluorescence) staining as well as the caveolin-1 and caspase-3 co-
localising (yellow staining around the cells in the merge field) signal on the 













Figure 33: TRAIL induces an increased in membrane-associated caspase-3 in HK-1 cells 
HK-1 cells were treated with TRAIL 25ng/ml for 6hr. Confocal analysis for caspase-3 and 











TRAIL induces peroxynitrite production in HK-1 cells 
Studies have reported ROS production upon TRAIL induction and that this 
oxidative stress mediates TRAIL-induced apoptosis. Thus experiments were 
carried out to investigate if ROS is being produced by TRAIL in the NPC 
system. 
 
HK-1 cells were treated with 25ng/ml of TRAIL for 2hr to 8hr and then 
subjected to flow cytometric analysis for ROS production using oxidant 
sensitive probe DCFDA (highly sensitive to peroxynitrite). Result (Fig 34) 
shows that oxidant is being produced in TRAIL-treated HK-1 cells from 4hr 
onwards. Furthermore, the pre-treatment of cells with FeTPPS for 1hr before 
addition of TRAIL is able to impair the oxidant production induced by TRAIL 
in the HK-1 cells (Fig 35). FeTPPS, a catalyst for peroxynitrite decomposition 
is able to bring down the oxidant produce by TRAIL. This suggests that the 
species of oxidant induced by TRAIL is peroxynitrite.  
 
 
Figure 34: TRAIL induces oxidant production in HK-1 cells 
HK-1 cells were treated with TRAIL 25ng/ml for 2hr, 4hr, 6hr and 8hr. Cells were harvested 
for flow cytometric analysis for oxidant production using oxidant sensitive probe DCFDA. 







































Figure 35: Antioxidant, FeTPPS scavenges oxidant production induced by TRAIL in 
HK-1 cells 
HK-1 was incubated with antioxidant, FeTPPS (25µM and 50µM) for 1hr followed by 6hr 
treatment with TRAIL 25ng/ml. Cells were harvested for flow cytometric analysis for oxidant 
production using oxidant sensitive probe DCFDA. Upper panel: Bar graph indicating the x-
fold increase in oxidant production. Data are expressed as means of fold increase ± S.D of at 
least three independent experiments. Lower panel: Density plots of forward scatter against 
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Peroxynitrite induces an increased in TMTC2 protein level in HK-1 cells  
TRAIL is able to increase TMTC2 protein level in HK-1 cells. Also, it induces 
peroxynitrite production in the cells. Thus could peroxynitrite be the 
messenger regulating the TMTC2 protein level?  
 
To answer the above question, the effect of peroxynitrite (LD50~200µM) on 
the total protein level for TMTC2 was assessed using western blotting. It was 
observed that peroxynitrite is able to increase the TMTC2 level in HK-1 cells 
(Fig 36). This corresponds to the effect observed with TRAIL, suggesting that 
peroxynitrite production induces by TRAIL is responsible for the increase in 







Figure 36: Peroxynitrite induces an increased in TMTC2 protein level in HK-1 cells 
HK-1 cells were treated with peroxynitrite 200µM for 4hr and 8hr. Whole cell lysates were 
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Antioxidant, FeTPPS abrogates the increase in TMTC2 protein level 
induced by TRAIL in HK-1 cells 
To further verify that peroxynitrite production induces by TRAIL causes the 
increase in TMTC2 level in HK-1 cells, antioxidant experiment was carried 
out.  
 
HK-1 cells were pre-treated with FeTPPS for 1hr before addition of TRAIL 
and the total protein level of TMTC2 was assessed by western blotting. 
FeTPPS, a catalyst for peroxynitrite decomposition is able to increase the rate 
of peroxynitrite degradation upon its production. It was observed that FeTPPS 
was able to reverse the increase in TMTC2 level induced by TRAIL in HK-1 
cells (Fig 37). This further shows that peroxynitrite is involved in the increase 








Figure 37: Antioxidant FeTPPS blocks TRAIL mediated increase in TMTC2 protein 
level in HK-1 cells 
HK-1 cells were incubated with FeTPPS for 1hr followed by 4hr and 8hr treatment with 














Pan-caspase inhibitor, ZVAD-fmk and knock-down of caspase-8 abolishes 
the increase in TMTC2 protein level induced by TRAIL in HK-1 cells 
As shown previously, in HK-1 cells, caspase activation begins at 2hr of 
TRAIL treatment (Fig 11A upper panel) and the increased in TMTC2 level 
was observed at 4hr of TRAIL treatment (Fig 31). According to the sequences 
of events, it seems that caspase activation is upstream of TMTC2 protein 
induction. To verify this, the effect of pan-caspase inhibitor, ZVAD-fmk on 
the TRAIL induction of TMTC2 was analysed.  
 
HK-1 cells were pre-treated with ZVAD-fmk for 1hr before addition of 
TRAIL and the total protein level of TMTC2 was assessed by western 
blotting. Fig 38A shows that ZVAD-fmk was able to abrogate the induction of 
TMTC2 by TRAIL in HK-1 cells. This observation supports that caspase 
activation is upstream of TMTC2 protein induction by TRAIL. 
 
Since caspase activation is upstream of TMTC2 protein induction by TRAIL, 
it would be of interest to know which caspase is involved. Silencing of 
caspase-8 and -3 were carried out in Hk-1 cells.  Fig 38B shows that knock-
down of caspase-3 has minimal effect on the induction of TMTC2 by TRAIL. 
On the other hand, the knock-down of caspase-8 was able to abrogate the 

























Figure 38: Pan-caspase inhibitor, ZVAD-fmk and knock-down of caspase-8 prevents 
TRAIL mediated increase in TMTC2 protein level in HK-1 cells 
A. HK-1 was incubated with pan-caspase inhibitor, ZVAD-fmk 25µM for 1hr followed by 4hr 
and 8hr treatment with TRAIL 25ng/ml. Whole cell lysates were then used to assay for 
TMTC2 by SDS-PAGE and western blotting. B. HK-1 cells were transiently transfected with 
either scrambled siRNA or siRNA against caspase-8 or caspase-3 and allowed to recover for 
24hr post transfection. HK-1 cells were subjected to TRAIL treatment at 25ng/ml for 3hr and 
6hr. Upper panel: Western blot showing knock-down of caspase-8 or caspase-3 proteins in 
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Pan-caspase inhibitor, ZVAD-fmk blocks peroxynitrite production 
induced by TRAIL in HK-1 cells 
Results have shown that both TRAIL-induced peroxynitrite production and 
TRAIL-induced caspase activation leads to TMTC2 induction in HK-1 cells. 
However the sequence of events is unknown, thus experiment was carried to 
evaluate the order of events. 
 
HK-1 cells were pre-treated with ZVAD-fmk for 1hr followed by TRAIL 
treatment for 6hr. The cells were then subjected to flow cytometric analysis 
for peroxynitrite production using oxidant sensitive probe DCFDA. The pre-
treatment of cells with ZVAD-fmk is able to impair the peroxynitrite 
production induced by TRAIL in the HK-1 cells (Fig 39). This data indicates 
that peroxynitrite may play a role as a downstream mediator to caspases in the 



































Figure 39: Pan-caspase inhibitor, ZVAD-fmk prevents peroxynitrite production induced 
by TRAIL in HK-1 cells 
HK-1 cells were incubated with pan-caspase inhibitor, ZVAD-fmk 25µM for 1hr followed by 
6hr treatment with TRAIL 25ng/ml. Cells were harvested for flow cytometric analysis using 
oxidant sensitive probe DCFDA. Upper panel: Bar graph indicating the x-fold increase in 
peroxynitrite production. Data are expressed as means of fold increase ± S.D of at least three 
independent experiments. Lower panel: Density plots of forward scatter against DCFDA 
































Antioxidant, FeTPPS confers partial protection against TRAIL-induced 
cell death in HK-1 cells 
TRAIL induces peroxynitrite production downstream of caspase activation in 
HK-1 cells. The peroxynitrite produced is involved in the TRAIL induction of 
TMTC2. So is peroxynitrite important in mediating TRAIL-induced cell death 
in the NPC system? 
 
To examine the importance of peroxynitrite in TRAIL-induced killing, the 
effect of antioxidant, FeTPPS was investigated. Prior addition of FeTPPS 
restored cell viability of TRAIL-treated HK-1 cells (Fig 40A) by around 20%, 
after 24hr of treatment. This was further validated with PI staining, assessing 
the extent of DNA fragmentation as a function of apoptosis after drug/s 
treatment. A similar result was obtained, pre-treatment of cells with FeTPPS 
decreases TRAIL-induced apoptosis from about 40% to 20% (Fig 40B). In 
addition, the processing and activation of caspases-8, -9 and -3 resulting from 
the treatment of TRAIL were also reduced by FeTPPS in HK-1 cells (Fig 41). 
On the whole, FeTPPS only confers partial protection against TRAIL-induced 




















































































Figure 40: Antioxidant, FeTPPS confers partial protection against TRAIL-induced cell 
death in HK-1 cells  
HK-1 cells were incubated with antioxidant, FeTPPS (25µM and 50µM) for 1hr followed by 
24hr treatment with TRAIL 25ng/ml. A. Upper panel: Crystal violet staining of viable cells 
after drugs treatment. Lower panel: Percentage of cell survival determined by crystal violet 
assay. Data are expressed as means ± S.D of at least 3 independent experiments. B. PI staining 
was performed for cell cycle analysis. Upper panel: Histogram representation of the cell 
cycle profile. Lower panel: Bar graph representation of the sub-G1 population. Data shown 




























































Figure 41: Antioxidant, FeTPPS confers partial inhibition of TRAIL-induced 
processing/activation of procaspases in HK-1 cells  
A. HK-1 cells were incubated with antioxidant, FeTPPS 50µM for 1hr followed by 3hr and 
6hr treatment with TRAIL 25ng/ml. Whole cell lysates were used to determine the activities 
of caspase-8, caspase-9 and caspase-3 using fluorescent-conjugated substrates. Data are 
expressed as means ± S.D of at least three independent experiments. B. HK-1 cells were 
incubated with antioxidant, FeTPPS 50µM for 1hr followed by 3hr treatment with TRAIL 
25ng/ml. Whole cell lysates were then used to assay for caspase-8, caspase-9 and caspase-3 
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Antioxidant, FeTPPS partially restores the colony forming ability of 
TRAIL-treated HK-1 cells 
Given the ability of FeTPPS to partially rescue HK-1 cells from TRAIL-
induced cell death upon short-term treatment, it would be of interest to look at 
the effect of FeTPPS in the long-term survival/proliferative capacity of tumour 
cells as well.  
 
HK-1 cells were pre-treated with FeTPPS for 1hr before exposure to TRAIL 
for 8hr. An equal number of cells were then seeded onto 100mm Petri dishes 
and allowed to form colonies over a period of 10 to 14 days. Upon staining by 
crystal violet stain, a marked reduction in colony formation for cells treated 
with TRAIL was observed and significantly more colonies were observed in 
cells pre-treated with FeTPPS (Fig 42). Thus, FeTPPS is able to partially 



























Figure 42: Antioxidant, FeTPPS confers partial restoration in tumour colony forming 
abilities of HK-1 cells on TRAIL treatment  
HK-1 cells were incubated with antioxidant, FeTPPS 50µM for 1hr followed by 8hr treatment 
with TRAIL 25ng/ml. The cells were then re-seeded onto 100mm petri dishes and allowed to 
form colonies over 10 to 14 days, followed by staining with crystal violet. Data shown are 
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Knock-down of TMTC2 decreases HK-1 cells’ sensitivity towards TRAIL 
From the observations gathered so far, TMTC2 seems to play a role in the 
TRAIL signalling cascade. It shows from Fig 24 that the more TRAIL 
sensitive HK-1 cells have a higher level of TMTC2 as compared to the less 
TRAIL sensitive C666-1 cells. This seems to suggest that the level of TMTC2 
in the cells is a reflection of the cells’ sensitivity towards TRAIL-induced cell 
death. Thus a series of knock-down and overexpression experiments were 
carried out to verify this. 
 
TRAIL sensitive HK-1 cells have a high level of TMTC2. If TMTC2 is an 
indication of the TRAIL sensitivity, then the knock-down of TMTC2 in HK-1 
cells would be able to rescue the cells from TRAIL-induced cell death. RNAi-
mediated interference of TMTC2 in HK-1 cells was carried out. The effect of 
TRAIL on HK-1 cells was assessed by looking at its cell viability and sub-G1 
populations. With the knock-down of TMTC2 (Fig 43A), the cell viability of 
TRAIL-treated HK-1 cells was restored by about 30% (Fig 43B). 
Correspondingly, TMTC2 knock-down also decrease the population of cells in 
the apoptotic sub-G1 fraction after 24hr of TRAIL treatment (Fig 43C). The 
processing and activation of caspases-8, -9 and -3 resulting from the treatment 
of TRAIL were also reduced with the knock-down of TMTC2 (Fig 44). The 
drop in TMTC2 level has made the HK-1 cells less sensitive to TRAIL-
induced cell death. This corroborates the postulation that the level of TMTC2 
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Figure 43: Knock-down of TMTC2 confers protection against TRAIL-induced apoptosis 
in HK-1 cells 
HK-1 cells were transiently transfected with either scrambled siRNA or siRNA against 
TMTC2 and allowed to recover for 48hr post transfection. HK-1 cells were subjected to 
TRAIL treatment at 25ng/ml for 24hr. A. Western blot showing the knock-down of TMTC2 
protein. B. Percentage of cell survival determined by crystal violet assay. Data are expressed 
as means ± S.D of at least 3 independent experiments. C. PI staining was performed for cell 
cycle analysis. Upper panel: Histogram representation of the cell cycle profile. Lower panel: 
Bar graph representation of the sub-G1 population. Data shown are representative of at least 3 
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Figure 44: Knock-down of TMTC2 blocks TRAIL-induced processing/activation of 
procaspases in HK-1 cells 
HK-1 cells were transiently transfected with either scrambled siRNA or siRNA against 
TMTC2 and allowed to recover for 48hr post transfection. HK-1 cells were subjected to 
TRAIL treatment at 25ng/ml for 6hr. A. Western blot showing the knock-down of TMTC2 
protein. B. Whole cell lysates were used to determine the activities of caspase-8, caspase-9 
and caspase-3 using fluorescent-conjugated substrates. Data are expressed as means ± S.D of 
at least three independent experiments. C. Whole cell lysates were then used to assay for 
caspase-8, caspase-9 and caspase-3 processing by SDS-PAGE and western blotting. 
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Overexpression of TMTC2 increases C666-1 cells’ sensitivity towards 
TRAIL 
To further elucidate the hypothesis that the level of TMTC2 in the cells is a 
reflection of the cells’ sensitivity towards TRAIL-induced cell death, C666-1 
cells with low level of TMTC2 was used for the subsequent experiments.  
 
TMTC2 was overexpressed in C666-1 cells before subjecting the cells to 
TRAIL trigger. The TRAIL sensitivity of C666-1 cells was assessed by its cell 
viability and sub-G1 populations. From Fig 45B, it was observed that 
overexpression of TMTC2 in C666-1 cells drops the cell viability of the 
TRAIL-treated cells by about 20%. Similar trend was also observed for the 
sub-G1 population, overexpression of TMTC2 in C666-1 cells increase the 
apoptotic population of the TRAIL-treated cells (Fig 45C). In addition, 
overexpression of TMTC2 also enhances the processing and activation of 
caspase-8, -9 and -3 in the TRAIL-treated C666-1 cells (Fig 46B and C). The 
overexpression of TMTC2 enhances C666-1 cells’ sensitivity to TRAIL. 
 
On the whole, results are suggestive of the link between the cell’s TMTC2 
level to its TRAIL sensitivity, with cells having high TMTC2 level being more 


















































































Figure 45: Overexpression of TMTC2 in C666-1 cells increases its sensitivity towards 
TRAIL- induced apoptosis 
C666-1 cells were transiently transfected with 4µg of TMTC2 plasmid for 48hr. Cells were 
then treated with TRAIL 25ng/ml for 24hr A. Western blot showing the overexpression of 
TMTC2 protein. B. Percentage of cell survival determined by crystal violet assay. Data are 
expressed as means ± S.D of at least 3 independent experiments. C. PI staining was performed 
for cell cycle analysis. Upper panel: Histogram representation of the cell cycle profile. 
Lower panel: Bar graph representation of the sub-G1 population. Data shown are 
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Figure 46: Overexpression of TMTC2 enhances TRAIL-induced processing/activation of 
procaspases in C666-1 cells 
C666-1 cells were transiently transfected with 4µg of TMTC2 plasmid for 48hr. Cells were 
then treated with TRAIL 25ng/ml for 8hr A. Western blot showing the overexpression of 
TMTC2 protein. B. Whole cell lysates were used to determine the activities of caspase-8, 
caspase-9 and caspase-3 using fluorescent-conjugated substrates. Data are expressed as means 
± S.D of at least three independent experiments. C. Whole cell lysates were then used to assay 
for caspase-8, caspase-9 and caspase-3 processing by SDS-PAGE and western blotting. 
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1. TRAIL, a potential therapeutics for nasopharyngeal carcinoma 
NPC is a non-lymphomatous, squamaous cell carcinoma occurring at the 
nasopharynx. It is very common in Southern China, parts of Southeast Asia 
and Mediterranean Basin with an incident rate of about 10-30 per 100 000 
persons (3). It is rank one of the top 6 cancer affecting men in Singapore.  
 
The treatment for NPC includes radiotherapy, chemotherapy and occasionally 
surgery. Currently the more common chemotherapeutic drugs available for 
NPC treatment include 5-Fluorouracil and Cisplatin (23, 24). However, as 
with all chemotherapy, the major drawback is the non-specific killing of the 
rapidly proliferating normal cells in addition to the cancerous cells. Thus the 
main aim of this project would be to look at alternative therapeutics that is 
more tumour specific.   
 
TRAIL, a member of the TNF family, interacts with the death receptors, DR4 
and DR5 and activates intracellular apoptotic pathway. It has received 
particular attention as a potential tumour specific cancer therapeutic because, 
it selectively induces apoptosis in a wide variety of transformed cells, but does 
not seem to be cytotoxic to normal cells, in vitro (161, 175) and in vivo (162, 
174). This resulted in a rapid development of cancer therapeutic agents that 
can activate this apoptotic pathway. The therapeutic agents developed include 
recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody 
(MAb) against DR4 and DR5. Phase I trials have established the safety and 
tolerability of these TRAIL agonists in patients. Phase II trials are currently 
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evaluating the therapeutic efficacy of TRAIL agonists as single agents or in 
combination with established cancer therapeutics (239-247).  
 
Taking the above into consideration, TRAIL would be the target of 
investigation in this study, looking at the possibility for it to be a therapeutic 
for NPC.  
 
1.1 TRAIL induces cell death in NPC 
The potential of TRAIL as a therapeutic for NPC was studied using two NPC 
cell lines HK-1 and C666-1.  
 
TRAIL interacts with the death receptors, DR4 and DR5 and activates 
intracellular apoptotic pathway. Thus to begin with, the basal expression levels 
of the two TRAIL death receptors in the NPC cell lines were being examined. 
It was observed that both HK-1 and C666-1 cells expressed DR4 and DR5 
(Fig 6A). Most importantly, these cells were able to express the receptors on 
their cell surface (Fig 6B), allowing TRAIL to gain access to the death 
receptors for the initial firing of the TRAIL-induced apoptosis signalling 
cascade. This indicates the possibility of TRAIL being able to elicit a death 
inducing response in the two NPC cell lines. The surface expression of the 
death receptors on the NPC cell lines only provides superficial evidences for 
TRAIL to be a potential NPC therapeutics. To this end, the effect of TRAIL in 
the two NPC cell lines was assessed. A dose response for TRAIL in the two 
NPC cell lines was established. TRAIL demonstrated apoptotic inducing 
ability in the NPC cells lines seen by the reduction in cell viability (Fig 7A), 
accompanied by apoptotic hallmarks like an increase in DNA fragmentation 
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(Fig 7B) as well as a significant increases in caspase processing and activities 
(Fig 11). The death inducing ability of TRAIL was more pronounce for HK-1 
as compared to C666-1 (Fig 7) although both DR4 and DR5 are highly 
expressed in C666-1 (Fig 6A). This could be due to the presence of EBV in 
C666-1. The presence of EBV has been shown to contribute to the TRAIL 
resistance of cancer cells by the induction of Bcl-XL and cFLIP. Thus the 
presence of EBV in C666-1 might be the contributor for its TRAIL resistance.  
 
The apoptotic inducing ability of TRAIL can be abrogated in the two NPC cell 
lines by the blocking of the death receptors, DR4 and DR5 with blocking 
antibodies (Fig 8) as well as the knock-down of the death receptors (Fig 9). A 
better survival, with the cells being less responsive to TRAIL-induced killing, 
was observed when the TRAIL-DR4 signalling cascade was being abrogated 
(Fig 8 and Fig 9). The blockade of the TRAIL-DR5 signalling cascade had 
little effect on the cells’ response to TRAIL-induced killing. This observation 
seems to suggest that DR4 is the more dominating death receptors than DR5 in 
the two NPC cell lines. A study by Bahtier M Kurbanov et. al. (295) showed 
that in melanoma cells, high sensitivity to TRAIL-induced apoptosis was 
characteristic for DR4 positive cells, whereas DR4 negative cells showed a 
less and delayed response or were resistant. The use of selective DR4 and DR5 
blocking antibodies unequivocally proved the prevalent role of DR4 in those 
melanoma cells, where it was expressed. Several other studies in cells from 
lung, colon and breast carcinoma (188, 296-298) also showed that DR4 is the 




Apart from the short term effect of TRAIL in the NPC cell lines, long term 
effect of TRAIL was also being assessed. The long term proliferative capacity 
of these TRAIL treated cells were also compromised, as observed in their 
inability to form colonies compared to untreated cells (Fig 10).  
 
Activation of caspases plays a major role in the execution of apoptosis. The 
caspase dependency of the TRAIL-induced apoptosis was highlighted when 
the loss in cell viability, caspases processing and activities was abolished with 
the use of the pan-caspase inhibitor ZVAD-fmk (Fig 12 and Fig 13). 
 
1.2 HK-1 and C666-1 cells engages a type II TRAIL response 
In TRAIL-induced apoptosis, when the extrinsic death receptors pathway 
independent of the intrinsic mitochondria pathway are employed to execute 
apoptosis, cells with this type of profile is known to be type I cells. Type II 
cells occur when both the extrinsic pathway and the intrinsic pathway are 
being employed. 
 
On TRAIL treatment, caspase-8 and -9, which is a typical caspase for the 
extrinsic and intrinsic death pathway respectively, was being activated in the 
NPC cell lines (Fig 11). The activation of caspase-9 suggests the engagement 
of the intrinsic mitochondria pathway in NPC cell lines. The dropped in 
transmembrane potential (Fig 14) and the released of mitochondria 
cytochrome c into the cytosol (Fig 15A) upon TRAIL treatment also suggest 
the involvement of the mitochondria in the TRAIL-induced killing.  
 
The release of cytochrome c from mitochondria has been thought to be an 
irreversible step for the apoptotic process (125). Under non-apoptotic 
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condition, cytochrome c should only be found in the mitochondria and should 
not be present in the cytosol of non-apoptotic cells. However, for the two NPC 
cell lines used, a basal level of cytosolic cytochrome c was detected in the 
control cells in the absences of any apoptotic trigger (Fig 15A).  Thus the 
question of interest would be why the control cells are not dyeing even though 
cytosolic cytochrome c is present. Recent studies suggest that the execution 
phase of apoptosis is highly regulated even after cytochrome c is released 
(299, 300). One of the possible levels of such regulation could be the redox 
state of cytochrome c. By using cytosol isolated from mammalian cells, 
Vilmante Borutaite and Guy C. Brown (301) found that oxidation of 
cytochrome c by adding cytochrome oxidase stimulates caspase activation, 
whereas reduction of cytochrome c by tetramethylphenylenediamine (TMPD) 
or yeast lactate dehydrogenase/cytochrome c reductase blocks caspase 
activation. Cells incubated with ascorbate plus TMPD to reduce intracellular 
cytochrome c strongly inhibits staurosporine-induced apoptosis and caspase 
activation but not cytochrome c release. This indicates that cytochrome c 
redox state can regulate caspase activation. They also showed that in 
homogenates from healthy cells, cytochrome c was rapidly reduced, whereas 
in homogenates from apoptotic cells added cytochrome c was rapidly oxidised 
by some endogenous process. This oxidation was prevented if mitochondria 
were removed from the homogenate or if cytochrome oxidase was inhibited by 
azide. This suggests that permeabilisation of the outer mitochondrial 
membrane during apoptosis functions not just to release cytochrome c but also 
to maintain it oxidised via cytochrome oxidase, thus maximising caspase 
activation. Others have also shown that reduced cytochrome c is ineffective at 
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inducing caspase activation if the cytochrome c is held reduced by reducing 
agents (302-304). Thus, even though a basal level of cytosolic cytochrome c 
are being detected in the two NPC cell lines, the cytosolic cytochrome c could 
be in a reduced form, thereby unable  to elicit a full apoptotic caspase 
activation cascades. In addition, it has also been demonstrated that specific 
nitration of tyrosines 46 and 48 makes cytochrome c assemble a non-
functional apoptosome.  Hence, the basal level of cytosolic cytochrome c  in 
the two NPC cell lines could be in a nitrated state, thereby resulting in a non-
functional apoptosome, unable  to elicit a full apoptotic caspase activation 
cascades. However, the cytosolic cytochrome c status has not been assessed 
and therefore more experiments are required to elucidate the postulation.  
 
The mitochondria involvement in the TRAIL-induced cell death was further 
demonstrated in the two NPC cell lines that overexpressed the Bcl-2 protein. It 
is known that members from the Bcl-2 protein family serve as regulators of 
mitochondria-mediated apoptosis, with Bcl-2 holding a prominent role in 
preventing mitochondrial outer membrane permeabilisation and downstream 
execution. Therefore, to decipher the involvement of the mitochondrial 
pathway in TRAIL-induced apoptosis, the effect of TRAIL in the two NPC 
cell lines overexpressing Bcl-2 was assessed.  Transient overexpression of 
Bcl-2 significantly blocked apoptosis induced by TRAIL (Fig 16), thus 
providing evidence for the involvement of the mitochondrial amplification 
pathway in the TRAIL-induced apoptosis in the two NPC cell lines. 
 
TRAIL has been known to trigger the death receptor pathway by the 
oligomerisation of the death receptors and in order to employ the intrinsic 
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mitochondria death pathway, a cross-talk mediator, tBid is required.  In the 
unprocessed form, Bid is unable to initiate such cross-talk between the two 
death pathways. Cross talking only occurs when the activated caspase-8 from 
the extrinsic death pathway cleaves Bid. This activated truncated tBid is then 
able to trigger the intrinsic death pathway. In the two NPC cell lines, Bid, 
which is the cross-talk mediator, was shown to be processed on TRAIL trigger 
(Fig 15B).  
 
On the whole, TRAIL is shown to be able to mobilise both the death receptor 
and the mitochondria pathway of apoptosis in the two cell lines. This suggests 
that the two NPC cell lines are of type II profile. 
 
1.3 TRAIL induces cell death as efficiently if not better than 
conventional NPC therapeutics 
It has been discussed above that TRAIL is able to induce apoptosis in the two 
NPC cell lines. However to study the possibility of TRAIL as an alternative 
NPC therapeutics, its “performance” as compared to the other conventional 
NPC therapeutics needs to be assessed.  
 
In the two NPC cell lines, TRAIL was able reduce cell viability as efficiently 
if not better than the two conventional drugs of 5-Fluorouracil and Cisplatin 
(Fig 17). Since TRAIL has been shown to have little activity as a single agent 
in clinical trials, its effect when used in combination with 5-Fluorouracil and 
Cisplatin are also being assessed in the two NPC cell lines (Data not shown). 
With the combination therapy, the drop in cell viability in the two NPC cell 




1.4 TRAIL induces cell death in NPC primary cells 
The experiments done so far are all based on cell lines. In order to be more 
conclusive on the possibility of TRAIL as an alternative NPC therapeutics, the 
effect of TRAIL on NPC primary cells were also carried out.   
 
TRAIL showed hopeful result in the NPC primary cells, inducing more than 
20% cell death in them using a TRAIL dose ranging from 100ng/ml to 
400ng/ml (Fig 18). Therefore TRAIL is a very promising potential alternative 
NPC chemotherapeutics. 
 
2. Atypical early caspase-3 activation was observed in TRAIL-
induced apoptosis in the NPC cell lines 
Collectively, the data shows encouraging result for TRAIL as an alternative 
NPC therapy. However, an interesting observation was made during the 
analysis; an atypical early activation of effector caspase-3 was observed (Fig 
11A). Caspase-3 was observed to be activated at around the same time as the 
initiator caspase-8.  
 
In a typical death-receptor mediated apoptosis, TRAIL binds to its cell surface 
death receptors, inducing their trimerisation.  Following which, adaptor 
proteins FADD are then recruited. This in turn mediates the recruitment of 
initiator procaspase-8 via its DED to form the DISC. At the DISC, procaspase-
8 molecules are activated by autoproteolysis (56, 65). The activated initiator 
caspases then activate effector procaspases such as caspase-3 to effect 
apoptosis (140). Thus in the typical death-receptor pathway, the effector 
caspase-3 is being activated at a later stage, downstream of the initiator 
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caspase-8. However, our data seems to show much earlier caspase-3 
activation, simultaneously with caspase-8 and it seems like caspase-3 could be 
the upstream caspase instead of the conventional initiator caspase-8. Hence the 
next question to address would be the possibility of caspase-3 being the 
upstream caspase in the NPC model. 
 
2.1 Is caspase-3 the upstream caspase? 
To elucidate such an atypical observation as discussed above, a knock-down 
experiment of caspase-8 and caspase-3 had been carried out to elucidate who 
is the upstream caspase.  
 
The knock-down of caspase-8 confers protection to the two NPC cell lines 
against TRAIL-induced cell death as indicated by the rescue in cell viability 
(Fig 19). Also, the processing and activities of caspase-8 and caspase-3 was 
abolished with the knock-down of caspase-8 (Fig 20). On the other hand, the 
knock-down of caspase-3 has minimal effect on the TRAIL-treated cells. 
From Fig 19, it was observed that knock-down of caspase-3 do not confers 
much protection to the two NPC cell lines against TRAIL-induced apoptosis 
as no significant rescue in cell viability was observed.  The effect of caspase-3 
knock-down on the processing and activities of caspase-8 and caspase-3 in the 
TRAIL-treated cells was also minimal (Fig 20). This result suggests that 
whatever little amount of caspase-3 left after the caspase-3 knock-down is still 
sufficient to elicit a strong death signal. Studies have also shown that very low 
procaspase-3 concentrations (~0.05 mM, compare with HeLa procaspase-3 
concentration of 0.12 mM) are sufficient to trigger apoptosis (305, 306). 
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The abrogation of the TRAIL-induced killing by the knock-down of caspase-8 
shows that caspase-8 is still the initiator caspase and caspase-3 acts 
downstream of caspase-8. Although caspase-3 does not seems to play a 
relevant role in the activation of caspase-8 in the TRAIL treated NPC cell 
lines, it is still a crucial mediator of apoptosis. It is required for some typical 
hallmarks of apoptosis and is indispensable for apoptotic chromatin 
condensation, apoptotic bodies formation and DNA fragmentation in all cell 
types examined. 
 
2.2 Atypical early caspase-3 activation seen in NPC cell line is due to 
its presence in the cell surface membrane, in close proximity to the 
DISC 
With caspase-3 still a downstream target of caspase-8 in the TRAIL signalling 
cascade, the question of the atypical early effector caspase-3 activation has yet 
to be answered. 
 
Such early activation could be due to the presence of caspase-3 in the plasma 
membrane lipid raft. Salah et. al. (307) showed that caspase-3 is found in the 
lipid rafts of untreated Jurkat cells and peripheral T-lymphocytes. They 
showed that caspase-3 is a component of the death-inducing signalling 
complex, in close proximity to caspase-8. In another study, caspase-3 was 
reported to be enriched within the caveolar fraction purified from cardiac 
endothelial cells and this suggests that caspase-3 may be targeted to plasma-
membrane associated substrates (308). The presence of caspase-3 in the 
membrane lipid rafts suggests its close proximity to the DISC even before 
death trigger. Thus upon death stimuli, due to the close proximity of caspase- 
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3 to the DISC, the activated caspase-8 could efficiently gain access to and 
activated the caspase-3. This could possibly result in the atypical early 
caspase-3 activation that we have observed upon the death trigger. 
 
The plasma membrane consists primarily of sphingolipids, cholesterol and 
other (glycerol) phospholipids. The lateral assemblies of sphingolipids 
(sphingomyelin being the most prevalent) and cholesterol that forms from the 
tight hydrophobic interactions between these molecules result in their 
segregation from other phospholipids into distinct microdomains, termed rafts 
(309-311). These microdomains could be isolated by virtue of their detergent 
insolubility and further characterised by identifying their high content of 
cholesterol and the presence of bona fide raft-associated proteins, such as 
caveolin and flotillin in the fractions after ultracentrifugation in a sucrose 
gradient density (312). Here it was shown that caspase-3 is found in the cell 
surface membrane in the two NPC cell lines as seen by its presence in the raft 
fractions by western blotting (Fig 21).  Further analysis by confocal 
microscopy confirmed that the caspase-3 formed at the cell surface membrane, 
co-localised with caveolin-1, the raft marker (Fig 22). Together, the results 
show that caspase-3 are found to be in the plasma membrane lipid raft of the 
NPC cell lines. In addition, from the results, it was observed that the more 
TRAIL sensitive HK-1 cells has more membrane-associated caspase-3 as 






3. Association of caspase-3 with TMTC2 in the cell surface 
membrane 
In literature, caspase-3 has not been shown to possess any membrane targeting 
signal. Based on iPSORT prediction software, it was also predicted that 
caspase-3 contains no signal peptide (Fig 23). Thus without any membrane 
localising signal, one possible way in which caspase-3 can gets associated to 
the cell surface membrane would be to “hitch” onto other membrane protein.  
 
To find out the protein partner to which caspase-3 is possibly binding to, 
membrane lipid rafts from HK-1 cells are extracted and subjected to caspase-
3-affinity co-immunoprecipitation. After which it was ran on a SDS-PAGE 
and the protein band of the possible interacting partner excised and send for 
MALDI TOF-TOF analysis (service provided by Protein and Proteomics 
Centre in department of biological science, NUS). A potential candidate, 
transmembrane and tetratricopeptide repeat containing 2 (TMTC2) protein 
was identified. 
 
TMTC2 is a very novel protein with few publications on it. It belongs to the 
TMTC family. To date, TMTC family has got 4 members, namely TMTC1, 
TMTC2, TMTC3 and TMTC4. Little is known about them. In literature, only 
TMTC3 has been shown to be involved in the endoplasmic reticulum stress 
response, by modulating proteasome activity and XBP-1 transcript expression 
(313). As for the rest of the members, their protein function still remains 
unknown. 
 
TMTC2 is encoded by the TMTC2 gene on chromosome 12 of the human 
genome. This 94KDa protein is annotated to be a multi-pass membrane 
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protein, containing 10 tetratricopeptide repeat (TPR) repeats (314). The TPR is 
a structural motif found in many proteins and these proteins are involved in 
cellular functions such as molecular chaperone complexes, anaphase 
promoting complexes, transcription repression complexes, protein import 
complexes and protein folding (315-317).  TPR mediates protein-protein 
interactions and the assembly of multi-protein complexes (318, 319). Thus 
TMTC2 is a possible candidate to which caspase-3 might be tethering to at the 
cell surface membrane. 
 
To get started, the expression of TMTC2 in the two NPC cell lines was first 
assessed. It was observed that both NPC cell lines expresses TMTC2 in their 
system, with the more TRAIL sensitive HK-1 cells expressing a higher level 
of TMTC2 as compared to the less TRAIL sensitive C666-1 cells (Fig 24). 
Due to the ease of detection of TMTC2 in the HK-1 cells, for the subsequent 
experiment on TMTC2, HK-1 cells will be use unless otherwise stated. 
 
TMTC2 has been annotated to be a membrane protein, thus experiment has 
been carried out to verify it. Result from the sub-cellular fractionation shows 
the localisation of the TMTC2 to the membrane-enriched fraction (Fig 25). 
This suggests that TMTC2 is at the cell surface membrane protein and is a 
possible protein target to which caspase-3 is associating with at the membrane. 
 
In order for the two proteins to associate together, they have to be located in 
the same sub-cellular compartment within the cell. Analysis on the cell 
membrane-enriched fraction and the lipid raft fraction showed that both 
TMTC2 and caspase-3 are present in the cell membrane (Fig 26). Co-
localisation of TMTC2 and caspase-3 only suggest the possibility of their 
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association at the cell membrane. Subsequent caspase-3-affinity co-
immunoprecipitation experiment on the whole cell lysates and lipid raft extract 
of HK-1 cells showed that TMTC2 is being pulled down together with 
caspase-3 (Fig 27). This shows that caspase-3 is associating with TMTC2 at 
the cell surface membrane. 
 
3.1 Knock-down of TMTC2 decreases the amount of membrane-
associated caspase-3 in HK-1 cells 
The affinity co-immunoprecipitation result presents the association of caspase-
3 and TMTC2 at the cell surface membrane. To further investigate the 
association of the two protein, knock-down and overexpression experiment 
had been carried on HK-1 and C666-1 respectively. 
 
In HK-1 cells, there is a high level of TMTC2 expression with a substantial 
amount of membrane bound caspase-3. If caspase-3 were to be associating 
with TMTC2 at the membrane, then the knock-down of TMTC2 in the HK-1 
cells would result in a drop in the membrane-associated caspase-3. This 
observation was demonstrated in Fig 28. Upon TMTC2 knock-down, a drop in 
TMTC2 itself in the cell membrane-enriched fraction was observed. With less 
TMTC2 in the cell surface membrane for caspase-3 to be associated with, a 
drop in the membrane-associated caspase-3 was observed. This was 
accompanied by a corresponding increase in the cytosolic-associated caspase-
3. With the knock-down of TMTC2, the total caspase-3 level in the cells 
remains unchanged. Thus those caspase-3 which are unable to be tethered to 
the membrane due to the drop in the membrane TMTC2 are now all localised 
to the cytosol. Further analysis by confocal microscopy confirmed that the 
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knock-down of TMTC2 results in a corresponding drop to the membrane-
associated caspase-3 (Fig 29). 
 
3.2 Overexpression of TMTC2 increases the amount of membrane-
associated caspase-3 in C666-1 cells 
On the other hand in C666-1 cells, minimal amount of TMTC2 as well as 
membrane-associated caspase-3 was detected. With the overexpression of 
TMTC2, an increase in the membrane-associated caspase-3 was expected. The 
overexpressed TMTC2 was observed to be localised to the cell surface 
membrane (Fig 30B). The increase in membrane TMTC2 in the C666-1 cells 
was accompanied by an increase in membrane-associated caspase-3 (Fig 30C).   
 
Collectively, caspase-3 which lacks the membrane targeting signal was found 
to be associating with TMTC2 at the cell surface membrane. 
 
The experiments carried out so far is only able to indicate the association 
between caspases-3 and TMTC2. More concrete evidence showing their 
interaction, whether direct or indirect, is still lacking. A few experiments can 
be done to further elucidate their interaction. One of which is the yeast two-
hybrid system. It is a molecular biology technique used to discover protein–
protein interactions. The premise behind the assay is the activation of 
downstream reporter gene by the binding of a transcription factor onto an 
upstream activating sequence (UAS). For the yeast two-hybrid screening, the 
transcription factor is split into two separate fragments, called the binding 
domain (BD) and activating domain (AD). The BD is the domain responsible 
for binding to the UAS and the AD is the domain responsible for the activation 
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of transcription. In this system, one of the protein of interest is expressed as a 
fusion to the BD and another protein expressed as a fusion to the AD. The 
vectors that express these fusion proteins together with the reporter vector are 
introduced into the yeast system. If there is a significant increase in expression 
of the reporter gene, it will indicate a direct interaction of the two proteins 
under study. However, a mammalian protein is sometimes not correctly 
modified in yeast and this can leads to false results. Thus a complementary 
study in the mammalian two-hybrid system might be needed. In this system, 
one of the protein of interest is expressed as a fusion to the Gal4 DNA-binding 
domain and another protein is expressed as a fusion to the activation domain 
of the VP16 protein of the herpes simplex virus. The vectors that express these 
fusion proteins are co-transfected with a reporter chloramphenicol 
acetyltransferase (CAT) vector into a mammalian cell line. The reporter 
plasmid contains a cat gene under the control of five consensus Gal4 binding 
sites. If the two fusion proteins interact, there will be a significant increase in 
expression of the cat reporter gene. Another method of studying protein–
protein interactions would be the fluorescence resonance energy transfer 
(FRET) assay. FRET uses two fluorophores, a donor and an acceptor. 
Excitation of the donor by an energy source (e.g. flash lamp or fluorometer 
laser) triggers an energy transfer to the acceptor if they are within a given 
proximity to each other. The acceptor in turn emits light at its given 
wavelength. Because of this energy transfer, molecular interactions between 
biomolecules can be assessed by coupling each partner with a fluorescent label 




4. TRAIL induces an increase in TMTC2 protein level in HK-1 cells 
With the involvement of TMTC2 in the TRAIL-induced apoptosis signalling 
cascade, the next question of interest would be if TRAIL has any effect on 
TMTC2. The preliminary data shows that TMTC2 protein levels were increase 
in the cleared cell lysates upon TRAIL exposure (Figure 31). The increase in 
TMTC2 level upon TRAIL treatment was also reflected in the cell membrane-
enriched fraction of the HK-1 cells (Fig 32). The increase in TMTC2 induced 
by TRAIL also resulted in a corresponding increase in membrane-associated 
caspase-3 (Fig 33). This seems to suggest the present of a positive feedback 
loop for the amplification of the death signal triggered by TRAIL, whereby 
TRAIL induces induction of TMTC2 protein level, which in turns “bring” 
more caspase-3 to the membrane for activation. 
 
4.1 TRAIL induces peroxynitrite production in HK-1 cells 
In a study by Lee MW et. al. (320), strong ROS accumulation upon TRAIL 
induction, with activation of caspases, followed by apoptosis in HeLa cells 
was demonstrated. The pre-treatment with gamma-glutamylcysteinylglycine 
or estrogen, both effective antioxidants, significantly attenuated TRAIL-
induced apoptosis through the reduction of ROS accumulation and diminished 
caspases activity. Taken together, they suggested that oxidative stress 
mediates TRAIL-induced apoptosis in HeLa cells. In another study, the effect 
of ROS on TRAIL-induced apoptosis in solid cancers was established by 
Izeredjene, K. et. al. (321). They found that the classic uncoupler of oxidative 
phosphorylation, CiCCP, induced a generation of ROS that enhanced TRAIL-
induced apoptosis in TRAIL-resistant human colon carcinoma cell lines 
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(RKO, HT29, and HCT8) with increased Bax translocation and caspase 
activation. The importance of ROS was demonstrated when scavenging ROS 
completely abrogated apical caspase-8 activation and further downstream 
events leading to cell death. 
 
The accumulation of ROS upon TRAIL induction has been illustrated in a lot 
of studies and that the ROS produced is important in mediating TRAIL-
induced apoptosis. So, in the NPC system, is ROS being produced upon 
TRAIL exposure?  
 
A similar occurrence was observed in the HK-1 model, where TRAIL was 
able to elicit ROS production (Fig 34) from 4hr after TRAIL trigger. The ROS 
production was detected using oxidant sensitive probe DCFDA. 
Conventionally, DCFDA has been used as a probe to detect H2O2. However in 
the HK-1 model, the used of catalase does not abrogated the ROS 
accumulation induced by TRAIL (Appendix 1), suggesting that H2O2 is not the 
ROS species being produced. After searching through the literature and the 
MolecularProbe handbook provided by Invitrogen, it was shown the DCFDA 
probe is reactive to a number of other oxidant and in particularly sensitive to 
peroxynitrite (Appendix 2). When FeTPPS, a catalyst for peroxynitrite 
decomposition was used, the production of oxidant brought about by TRAIL 
in HK-1 cells was abrogated (Fig 35). This shows that the species of oxidant 






4.2 TRAIL mediated production of peroxynitrite induces the 
increased in TMTC2 protein level in HK-1 cells 
Consequences of exposure of cells to peroxynitrite are the induced expression 
of genes such as c-fos (322), heme oxygenase-1 (323), or the growth arrest 
and DNA damage-inducible (Gadd) proteins 34, 45, 153 (324), and the 
induction of apoptosis (325-328). As peroxynitrite and TMTC2 are being 
induced by TRAIL in the HK-1 cells, could peroxynitrite be the messenger for 
the TMTC2 induction caused by TRAIL?  
 
Preliminary result shows that the direct addition of peroxynitrite to HK-1 cells 
is able to increase the TMTC2 protein level (Fig 36). This indicates that 
peroxynitrite could be the inducer for the increase in TMTC2 protein level in 
the TRAIL-treated HK-1 cells. Further experiment with FeTPPS shows that 
when the production of peroxynitrite is blocked, the induction of TMTC2 by 
TRAIL was also abrogated (Fig 37). This shows that the TRAIL mediated 
induction of TMTC2 is dependent on the production of peroxynitrite by 
TRAIL.  
 
Following the sequence of events, upon TRAIL trigger, caspase is being 
activated at 2hr followed by peroxynitrite production and TMTC2 induction. 
Based on experiment with pan-caspase inhibitor, ZVAD-fmk, it was observed 
that the blockade of caspase activation abolished both the TMTC2 induction 
by TRAIL (Fig 38A) as well as the TRAIL mediated peroxynitrite production 
(Fig 39). This verify that caspase is being activated upstream of peroxynitrite 
accumulation and TMTC2 induction. In addition, it was shown that caspase-8 
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is responsible for this event (Fig 38B) as the knock-down of caspase-8 is able 
to inhibit the induction of TMTC2 by TRAIL.  
 
Till this point, how TRAIL causes the increase in TMTC2 protein level, 
whether is it at the transcriptional, translational or protein stability level, is still 
unknown. Experiments need to be carried out to verify it. If regulation were at 
the transcriptional level, an up regulation of the TMTC2 mRNA level would 
be detected by RT-PCR and the increase in TMTC2 mRNA as well as the 
protein will be abrogated when transcriptional inhibitor, actinomycin D is 
being used. If no change occurs at the TMTC2 mRNA level, then the 
regulation could be at the translational level. The use of protein synthesis 
inhibitor, cycloheximide will be able to reverse the effect of TRAIL-induced 
increase in TMTC2 protein. If none of the above is able to explain the 
accumulation of TMTC2 protein upon TRAIL exposure, then the next possible 
level of regulation would be at the protein stability. A more dramatic increase 
in TRAIL-induced TMTC2 accumulation would be observed in MG-132 
(proteasome inhibitor) treated cells if regulation is at the protein stability level. 
A chase experiment could also be done to check if the TMTC2 protein 
turnover rate was significantly altered with TRAIL treatment. 
 
Preliminary mRNA data (Data not shown) by a colleague from the laboratory 
showed that upon TRAIL treatment no changes was observed for the TMTC2 
mRNA level. This suggests that the induction of TMTC2 by peroxynitrite does 
not occur at the transcriptional level. Thus most probably the effect of 
peroxynitrite on TMTC2 induction is at the protein stability level, which 




As mentioned earlier, peroxynitrite is a highly reactive compound.  In order 
for it to have any effect on the membrane-associated TMTC2, the source of 
peroxynitrite has to be near the protein. Since peroxynitrite is formed from the 
extremely rapid, diffusion limited reaction between superoxide anion and 
nitric oxide, it is suggested that the source of reactants to be at the membrane. 
It has been shown that endothelial nitric oxide synthase and NADPH oxidase 
are present at the membrane lipid raft. Thus they are the likely source of nitric 
oxide and superoxide anion for the formation of peroxynitrite at the membrane 
to effect TMTC2. However more experiments need to be done to verify it. 
 
4.3 Relevance of TRAIL-induced peroxynitrite production in TRAIL-
induced apoptosis in HK-1 cells 
In literature, a lot of studies have shown the importance of oxidative stress to 
enhance and mediate TRAIL-induced apoptosis. When oxidative stress is 
being blocked by anti-oxidant, the killing ability of TRAIL will be abolished. 
In the HK-1 model, we have demonstrated that upon TRAIL treatment, 
peroxynitrite is being produced at 4hr onwards. Thus in this section, we aim to 
decipher if peroxynitrite is critical for TRAIL-induced apoptosis in the HK-1 
model.  
 
When peroxynitrite production induced by TRAIL is being blocked by 
FeTPPS, partial rescue in cell viability in the TRAIL-treated HK-1 cells was 
observed (Fig 40A). This was further verified by the drop in the apoptotic sub-
G1 population shown in Fig 40B. In addition, the processing and activation of 
caspases-8, -9 and -3 resulting from the treatment of TRAIL were also reduced 
by FeTPPS (Fig 41). Apart from these short term assay, long term colony 
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forming assay was also employed. It was shown that FeTPPS is able to 
partially restore the colony forming ability of TRAIL-treated HK-1 cells (Fig 
42). If peroxynitrite production is indeed critical for TRAIL-induced killing, 
then one would see a complete rescue of the HK-1 cells when the TRAIL-
induce peroxynitrite production is being prevented by FeTPPS. However, 
from the results, FeTPPS was only able to induce a partial rescue on the 
TRAIL-treated HK-1 cells. This finding show that TRAIL mediated 
peroxynitrite production is essential but insufficient to elicit a complete 
apoptotic response. The peroxynitrite induced by TRAIL might be acting as a 
second messenger to amplify the whole death signalling cascade in HK-1.   
 
5. TMTC2 expression level reflects the TRAIL sensitivity of the cells 
Results of this study have demonstrated that the atypical early caspase-3 
activation is due to its association with TMTC2 at the cell surface membrane, 
in close proximity to the DISC, thereby allowing efficient caspase-3 activation 
upon death trigger. It was also shown that TRAIL is able to induce TMTC2 
level in HK-1 cells. So, moving on, what is the physiological significance of 
TMTC2 in the TRAIL-induced apoptosis in the NPC model? 
 
From the results collected so far, a differential in the expression level of 
TMTC2 was observed in the two NPC cell lines used. The TMTC2 level was 
observed to be higher in HK-1 cells as compared to C666-1 cells. The two cell 
lines also exhibits differences in their response towards TRAIL-induced 
apoptosis. The HK-1 cells are shown to be more sensitive towards TRAIL-
induced killing than C666-1 cells. Therefore, it was hypothesize that the level 
of TMTC2 within the cells could be a reflection of its sensitivity towards 
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TRAIL-induced killing, with cells having higher amount of TMTC2 to be 
more sensitive towards TRAIL trigger.  
 
5.1 Knock-down of TMTC2 decreases HK-1 cells’ sensitivity towards 
TRAIL 
To decipher the above mentioned hypothesis, the HK-1 model was first used. 
The HK-1 cells being sensitive towards TRAIL-induce killing also expressed a 
high amount of TMTC2. RNAi technology was engaged to bring down the 
level of TMTC2 within the HK-1 cells and its TRAIL sensitivity was assessed. 
If the postulation was true, knocking down of TMTC2 in the HK-1 cells would 
be able to protect the cells against TRAIL-induced apoptosis. The result 
obtained was reflective of what was being postulated. The knock-down of 
TMTC2 protects the HK-1 cells against TRAIL-induced killing. The cell 
viability of TRAIL-treated HK-1 cells was restored back from about 45% to 
70% (Fig 43B) after the knock-down of TMTC2 and this was also reflected in 
the drop in apoptotic sub-G1 population (Fig 43C). In addition, the processing 
and activation of caspases-8, -9 and -3 resulting from the treatment of TRAIL 
were also reduced with the knock-down of TMTC2 (Fig 44). 
 
5.2 Overexpression of TMTC2 increases C666-1 cells’ sensitivity 
towards TRAIL 
Next, the hypothesis was tested in the C666-1 model. The C666-1 cells 
exhibiting a less TRAIL sensitive phenotype expresses a minimal amount of 
TMTC2. According to the postulation, high level of TMTC2 indicates a 
TRAIL sensitive phenotype, thus overexpression of TMTC2 in the C666-1 
cells would be able to sensitise the cells towards TRAIL-induced apoptosis. 
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This prediction was observed in the result obtained. From Fig 45B, it was 
observed that overexpression of TMTC2 in C666-1 cells drops the cell 
viability of the TRAIL-treated cells from about 75% to 56%. Similar trend 
was also seen in the sub-G1 population, overexpression of TMTC2 in C666-1 
cells increase the apoptotic population of the TRAIL-treated cells (Fig 45C). 
In addition, overexpression of TMTC2 also enhances the processing and 
activation of caspase-8, -9 and -3 in the TRAIL-treated C666-1 cells (Fig 46). 
 
Collectively, the results support the idea that the level of TMTC2 within the 
cells is reflective of its TRAIL sensitivity, with high level of TMTC2 
indicating a TRAIL sensitive phenotype. However, to have a more definite 
and robust conclusion, the studies have to include primary cells, cell lines of 
other origin, like the cervical cancer cell lines, lung carcinoma cell lines or the 
colon cancer cell lines as well as more NPC cell lines. If the hypothesis is 
applicative across cell lines, then the level of TMTC2 could possibly be used 















Nasopharyngeal carcinoma is a disease with distinct ethnic and geographic 
distribution. This tumour is relatively rare in the Western world, but represents 
a significant disease burden in Southern China and Southeast Asia.  Despite 
being potentially curable at an early stage, more than 50% of patients who 
have nasopharyngeal carcinoma present with advanced loco-regional disease, 
which results in a poor prognosis. 
 
 Throughout the last decade, important advances have been made with regard 
to the management and monitoring of NPC. Several prospective clinical trials 
have unanimously confirmed the efficacy of concurrent chemoradiotherapy. 
When radiotherapy is used alone, survival rates range from 40-50%, while the 
use of combination of radiation therapy and chemotherapy allows long-term 
survival rates of 55-80%. However, as with all cancer therapy, major 
challenge to find better ways to specifically target tumours with drugs and 
chemotherapeutic agents in order to provide a more effective, localised dose 
and to minimise exposure of healthy tissue in other parts of the body to the 
potentially adverse effects of the treatments still remain.  
 
TRAIL has received particular attention as an excellent strategy for eliciting 
tumour specific cell death because it selectively induces apoptosis in a wide 
variety of transformed cells with no toxicity to normal cells. This study 
provides evidence for the first time, the potential of TRAIL as a NPC 
therapeutic. TRAIL has been shown to induce apoptosis in two NPC cell lines, 
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HK-1 and C666-1, in a caspase-dependant manner. In addition, TRAIL also 
exhibits cell death inducing capabilities in NPC primary cells.  
 
Serendipitously, a non-classical early activation of effector caspase-3 in the 
NPC model is identified. This is due to the presence of caspases-3 in the cell 
surface membrane lipid raft in association with a novel membrane protein, 
TMTC2. The presence of caspases-3 at the lipid raft allows the close 
proximity of caspsase-3 to the DISC in the lipid rafts even before death 
trigger.  As a result, upon trigger, caspases-3 can be activated at a much earlier 
time point.  
 
Furthermore, this study also suggests that the level of TMTC2 within the cells 
is reflective of the cell’s sensitivity towards TRAIL. This suggests that 
TMTC2 could be a novel biomarker to indicate the TRAIL responsiveness in 
the clinical setting. Then again, more extensive and robust validation in vitro 
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Supplemental figure 1: Catalase does not scavenge the ROS production induced by 
TRAIL in HK-1 cells.  
HK-1 was incubated with catalase (4000U) for 1hr followed by either  6hr treatment with 
TRAIL 25ng/ml or 1hr treatment with H2O2 (300uM) as a positive control. Cells were 
harvested for flow cytometric analysis for ROS production using oxidant sensitive probe 
DCFDA. Upper panel: Bar graph indicating the x-fold increase in ROS production with 
TRAIL and catalase. Lower panel: Bar graph indicating the x-fold increase in ROS 
production using H2O2 as a positive control. Data are expressed as means of fold increase ± 


















































Reactive Oxygen Species (ROS) ROS Generation Method H2DCFDA  
Hydrogen peroxide (H2O2) 100 µM of H2O2 190 
Hypochlorite anion (
–
OCl) 3 µM (final) of 
–
OCl 86 
Nitric oxide (NO) 100 µM of 1-hydroxy-2-oxo-3-(3-aminopropyl)-3-methyl-1-triazene (NOC-7) 150 
Peroxyl radical (ROO•) 100 µM of 2,2'-azobis(2-amidinopropane), dihydrochloride (AAPH) 710 
Peroxynitrite anion (ONOO
–





O2) 100 µM of 3-(1,4-dihydro-1,4-epidioxy-1-naphthyl)propionic acid 26 
Superoxide anion (•O2
–
) 100 µM KO2 67 
Autooxidation 2.5 hours exposure to fluorescent light source 2000 
 
Adapted from the MolecularProbes handbook from Invitrogen 
 
Supplemental table 1: Fluorescence response of dichlorodihydrofluorescein diacetate (H2DCFDA) to various reactive oxygen species (ROS) 
 
 
 
